

GENERATIONS OF IMPACT

The mission of
The Leukemia &
Lymphoma Society
(LLS) is to cure
leukemia, lymphoma,
Hodgkin's disease
and myeloma, and
improve the quality
of life of patients
and their families.

Table of Contents

CELEBRATING 70 YEARS	2
SPOTLIGHTING OUR IMPACT	4
ADVANCING OUR MISSION IN 2019	6
TAKING ON CHILDREN'S CANCER FROM EVERY DIRECTION	8
ACCELERATING CURES	14
DRIVING CLINICAL TRIAL INNOVATION, EDUCATION AND ENROLLMENT	18
HELPING PATIENTS THROUGHOUT THEIR CANCER EXPERIENCE	22
BREAKING DOWN BARRIERS TO CARE	26
DRIVING SUPPORT ACROSS THE COUNTRY	30
PARTNERING FOR PROGRESS TOWARD CURES	32
RECOGNIZING OUR SUPPORTERS	34
ACKNOWLEDGING OUR EXTRAORDINARY VOLUNTEERS	36
FINANCIALS	38
ACKNOWLEDGMENTS	57

Please visit www.LLS.org/AnnualReport to read our full Fiscal Year 2019 Annual Report, including financials and acknowledgments.

CELEBRATING 70 YEARS

A Letter from our Leadership



Dear Friends,

You are part of our story—the story of The Leukemia & Lymphoma Society (LLS)—which begins with one family’s hope and will end with curing cancer in our lifetime.

Rudolph and Antoinette Roesler de Villiers founded LLS in 1949 after losing their 16-year-old son Robbie to leukemia. Determined to spare other families the devastating loss of a child, the de Villiers set out to transform cancer treatment and care. As an organization founded by a family for families, our vision is rooted firmly in the de Villiers’ relentless drive to create a world without blood cancer.

Since our founding, generations of patients, survivors, caregivers, families, volunteers, researchers, healthcare professionals and supporters have joined our quest for cancer cures. In 2019, LLS

celebrated our 70th anniversary by looking to inspiration of the past to propel us forward. To mark the occasion, we invited our global community to help us grow a digital family tree on www.LLS.org by sharing stories of impact.

Stories like that of Dr. James Holland, who was a trailblazing researcher. In 1955, LLS awarded a grant to Dr. Holland, whose discovery helped establish the first standard of care for children with leukemia. Today, this story resonates even more in light of our recent launch of The LLS Children’s Initiative, a \$100 million comprehensive endeavor to deliver cures and better care to children with cancer.

Here at LLS, beating cancer is in our blood. Over the past 70 years, we have invested nearly \$1.3 billion in cutting edge research worldwide, fueling virtually every critical advancement in blood cancer treatment, including pioneering chimeric antigen receptor (CAR) T-cell immunotherapies that supercharge patients’ own immune cells to attack cancer. Many of these groundbreaking treatment approaches, first discovered in blood cancer, are now being tested in clinical trials for other cancers and diseases, such as breast, lung, pancreatic and prostate cancer.

We believe there is no one way to beat cancer. The future of cancer treatment hinges on giving the right treatment to the right patient at the right time. LLS is bringing the promise of precision medicine and immunotherapy to more patients in urgent need across every aspect of our mission work.

At the same time, we are relentless about helping patients, caregivers and families throughout their entire cancer experience to ensure they have access to care. LLS is the leading source of free blood cancer information, education and support for patients, survivors, caregivers, families and healthcare professionals. And through our nationwide

grassroots network of more than 50,000 active online volunteers, we drive lifesaving policies that accelerate the development of new cancer treatments and break down barriers to care.

While we've made incredible progress, blood cancers are the second leading cause of cancer deaths in the U.S.—a sobering reminder that we have more work to do. We need to change fundamentally how children with cancer are treated. We need to advance new and efficient clinical trial models to deliver more breakthroughs, and importantly, we need to help patients access these trials. And we need to take bold action for patients against the staggering cost of cancer care.

Every facet of our mission is working in harmony to put patients first and address these priorities. As a global leader in the fight to end cancer, with your support, we press on with unwavering dedication.


Gratefully,



Louis J. DeGennaro, PhD
President and Chief Executive Officer



Jorge Benitez
Chair of the Board



“Everyone is supposed to fulfill a certain purpose in life; Robbie’s seems to have been to make others happy with his joyful, inspiring nature, his wit and knowledge, and as young as he was—in fact hardly more than a child—to earn the right not to be forgotten.”

— **Rudolph Roesler de Villiers**

SPOTLIGHTING OUR **IMPACT**

Our work has helped millions impacted by cancer.

Since the 1960s, survival rates for many blood cancer patients have doubled, tripled or even quadrupled. What's more, we've seen an average decline of 32 percent in blood cancer death rates since the 1990s. That's the power of the LLS mission. By funding pioneering cancer research to advance treatments and cures and helping patients and families access the care they need, we are saving and improving the lives of patients and giving hope to countless families across the globe. But we won't stop until we achieve a world without blood cancer.




“Thanks to LLS, a new treatment was available each time I relapsed, and those new treatments provided hope for my family and me.”

— **Peter Pearson, a three-time cancer survivor first diagnosed with Hodgkin lymphoma in 2013**


Peter participated in a clinical trial for a targeted therapy called brentuximab vedotin (Adcetris®), which LLS-funded research helped advance. In 2018, the FDA approved this therapy in combination with chemotherapy to treat newly diagnosed patients with advanced Hodgkin lymphoma, representing the first change in the standard of care for the disease in 40 years. Today, Peter and his family raise funds for LLS through Big Climb, Light The Night and Pennies for Patients.

5-Year Relative Survival Rates (Percentage)



Since the 1960s, survival rates for many blood cancer patients have doubled, tripled or even quadrupled.

Deaths Per 100,000 People



We've seen an average decline of 32 percent in blood cancer death rates since the 1990s.

NEARLY

\$1.3B

INVESTED IN BLOOD CANCER RESEARCH WORLDWIDE SINCE 1949

LEADING SOURCE

OF FREE EDUCATION AND SUPPORT FOR BLOOD CANCER PATIENTS AND FAMILIES

MORE THAN

50,000

ACTIVE ONLINE VOLUNTEERS ADVOCATE FOR LIFESAVING POLICIES

ADVANCING OUR MISSION **IN 2019**

Thanks to you, our 70th year was the most impactful one yet at LLS.



LLS HELPED ADVANCE

46 OF THE 53

BLOOD CANCER TREATMENT OPTIONS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SINCE 2017.



IN ADDITION TO OUR BEAT AML MASTER CLINICAL TRIAL, LLS SUPPORTED

MORE THAN 240

CUTTING EDGE RESEARCH GRANTS AND **22** THERAPY ACCELERATION PROGRAM (TAP) PARTNERSHIPS WORLDWIDE.



LLS HAS SEEN PROGRESS ON

75 PERCENT

OF THE 31 POLICY RECOMMENDATIONS WE PUT FORTH TO CONGRESS, AIMED AT LOWERING THE COST OF CANCER CARE FOR PATIENTS WHILE PROTECTING ACCESS TO QUALITY CARE.



LLS VOLUNTEER ADVOCATES SENT

MORE THAN 8,400

LETTERS IN SUPPORT OF THE CANCER DRUG PARITY ACT, INTRODUCED TO CONGRESS TO ENSURE ACCESS TO ALL CANCER TREATMENTS, REGARDLESS OF HOW TREATMENTS ARE ADMINISTERED.



WHAT'S THE LATEST IN BLOOD CANCER RESEARCH?

Lee Greenberger, PhD, *Chief Scientific Officer at LLS*, shares what key trends mean for patients.

1. The genomics revolution is here. Blood cancers—which consist of more than 100 different types of diseases—are complex, but we're cracking the code, thanks to new genomic technologies. Equipped with powerful molecular methods and a deeper understanding of our genetic blueprint, we're learning more about what causes blood cancer and why certain therapies work and why some fail.

Your support helped LLS invest **\$283.9 MILLION** in our mission this year, bolstering research, education and support, and policy and advocacy efforts that helped put patients and their families first.



LLS INFORMATION SPECIALISTS
RESPONDED TO

MORE THAN 20,000

INQUIRIES FROM PATIENTS AND
CAREGIVERS IN 2019 ALONE.



LLS CLINICAL TRIAL
NURSE NAVIGATORS PROVIDED

MORE THAN 600

PATIENTS WITH IN-DEPTH CLINICAL TRIAL
NAVIGATION AND SUPPORT.



THIS YEAR, OUR LIGHT THE NIGHT,
MAN & WOMAN OF THE YEAR
AND STUDENTS OF THE YEAR CAMPAIGNS

BROKE FUNDRAISING RECORDS

AS DEDICATED PARTICIPANTS DROVE MORE
SUPPORT FOR OUR MISSION THAN EVER BEFORE.



THANKS TO OUR INCREDIBLE
SUPPORTERS, WE ACHIEVED OUR

\$125 MILLION

FUNDRAISING GOAL FOR OUR
COMPREHENSIVE EFFORTS TO
BEAT ACUTE MYELOID LEUKEMIA (AML).

2. Precision medicine is on the rise. Chemotherapies destroy cancer cells, but also damage normal cells, causing substantial side effects. Today, more recently approved oral targeted therapies attack blood cancer cells specifically, while sparing healthy cells with impressive results. For example, the FDA-approved combination of venetoclax (Venclexta®) and obinutuzumab (Gazyva®) marks a new chemotherapy-free, front-line treatment for chronic lymphocytic leukemia. LLS has supported research advancing venetoclax for the past 15 years. Venetoclax, when used in combination with conventional chemotherapy, is also a game changer for AML.

3. The golden age of immunotherapy continues.

LLS is advancing different approaches that activate the immune system to fight cancer, including CAR T-cell immunotherapies and cancer vaccines. We're exploring every avenue to improve CAR T-cell therapy so that more patients with blood cancer achieve long-lasting disease control.

4. Prevention is the new frontier. Advances in genomics are allowing us to identify individuals who are at a higher risk of developing blood cancer years before it might occur with the use of a blood test. Researchers are also exploring how to prevent early precursor diseases from progressing to more serious blood cancers.



“I stand in defiance against childhood cancer. Losing my son Zach was unimaginably devastating, but his struggle makes me all the more relentless about accelerating better treatments and care, so we can save the lives of more children and spare others from life-altering, long-term side effects.”

— Julie Guillot, Volunteer Chair, Pediatric Partnerships and Outreach at LLS



BY THE NUMBERS

APPROXIMATELY 80%

OF CHILDHOOD CANCER SURVIVORS DEVELOP ONE OR MORE CHRONIC HEALTH CONDITIONS AS A RESULT OF TREATMENT

IN THE LAST 40 YEARS, ONLY

4 ONCOLOGY DRUGS

HAVE BEEN APPROVED FOR FIRST USE IN CHILDREN

Taking on Children's Cancer from Every Direction

Fighting for Children with Cancer

Julie Guillot never imagined the harrowing struggle that would follow after her eldest son, Zach, was diagnosed with acute myeloid leukemia (AML) at the age of 5. For four years, Zach endured brutal chemotherapy, radiation, fevers, unyielding nausea and months confined to three different hospitals. A fan of superheroes, he faced the daunting regimen with bravery. But the intensity of his treatments took a tremendous toll. Sadly, Zach passed away after his third bone marrow transplant. "I won't stop fighting for Zach. I am determined to do as much as I can so other families don't have to go down this terrible path," says Julie. Today, Julie is an influential parent advocate and LLS volunteer who is dedicated to speeding safer, more curative therapies for children.

Delivering Cures and Better Care

For many childhood cancers, chemotherapies developed decades ago remain the standard of care and simply don't work well enough. Too many children succumb to their cancer. Survival rates for high-risk forms of blood cancer, such as AML, are especially poor. For those who do survive, the long-term effects of treatment can cause life-threatening complications and secondary illnesses and cancers.

LLS is disrupting the status quo with our bold vision: we want children not only to survive cancer, but thrive in their lives after treatment. That's why we launched **The LLS Children's Initiative: Cures and Care for Children with Cancer**, a full-scale, multi-year endeavor to take on children's cancer from every direction.

"Every young life lost to cancer is one too many. We must do better. With The LLS Children's Initiative, we will," says Gwen Nichols, MD, LLS Chief Medical Officer.

ABOUT 40%

OF PEDIATRIC CANCERS
ARE BLOOD CANCERS



King, diagnosed with ALL

Taking on Children's Cancer from Every Direction *(cont.)*

Overcoming Obstacles to Progress

For too long, children have been treated with a one-size-fits-all approach, despite cancer behaving differently in children than in adults. "Children are not little adults; they need therapies that are designed just for them," says Dr. Nichols. But given the relatively small patient population, there has not been enough incentive for the private sector to pursue pediatric drug development.

Beyond research, there are regulatory hurdles and access issues, including financial and geographic barriers, which stand between patients and the care they need.

Only LLS has the proven track record, leadership and visionary supporters needed to usher in a new era of pediatric cancer treatment and care.

Our goal is to revolutionize the standard of care for children with cancer, providing them with safer, more effective treatments that rely less on chemotherapies that harm healthy cells in the body.

“When a child is diagnosed with cancer, it affects the entire family. The support we received from the two LLS programs helped us focus on taking care of King and made us feel less alone in our journey. King has been dealing with cancer for most of his young life, and has a long road ahead of him still. But we are hopeful that with LLS leading the charge, more children will survive cancer and thrive in their lives after treatment.”

— Shameeza Singh, King's mother

King was diagnosed with high-risk acute lymphoblastic leukemia (ALL) in June 2016 at the age of 2. His treatment plan included three and a half years of daily chemotherapy. He took 75 pills per month, in addition to intravenous and spinal chemotherapy. During this time, he experienced severe complications, including brain swelling, nerve damage, painful mouth sores and more. His family received support from LLS through our Urgent Need Program and Patient Aid Program. In October 2019, King completed chemotherapy, but continues to battle the chronic side effects from his treatment and a lifelong genetic disorder called G6PD deficiency. King and his family spend their time advocating and spreading awareness about pediatric cancer.



Austin has been cancer free for six years, thanks to an LLS-supported CAR T-cell immunotherapy.

SPECIAL THANKS TO OUR CHILDREN'S INITIATIVE SUPPORTERS

Founding Partners \$1 million and above

Anonymous
The Harry T. Mangurian Jr. Foundation
Joan and Paul Rubschlager
The Wawa Foundation

\$500,000–\$999,999

The Don & Lorraine Freeberg Foundation
Lynne and Greg O'Brien
WWE

\$250,000–\$499,999

Anonymous (2)
Amgen Inc.
Orokawa Foundation
University of California San Francisco
University of Colorado Anschutz Medical Campus
University of Florida

\$100,000–\$249,999

Sara Asma & the Moore Family
William and Tamea Bock
The Boldt Family Philanthropy Fund
The Escher Foundation
F.M. Kirby Foundation
The Family and Friends of the Bock Family
Higgins Family Charitable Foundation
James and Lisa LaTorre
Nimick Forbesway Foundation

\$10,000–\$99,999

Anonymous
ACE Family Foundation
John Scott Black
Angela Blank
Bobby & Steve's Auto World Youth Foundation
The Breyfogle Family
Charles and Chris Carroll
CURE Childhood Cancer
Kim Dobbs
Enquirer Foundation
The Family of Kent Ribordy
Dianne Franco
Herber Family/High Five Foundation
Jack Buncher Foundation
Kristen and Doug Johanson
The Kayleen Larson Legacy Foundation
Janice and Larry Lowder
Lydia Odle
Marla Persky and Craig Heberton
Cherie and Fredrick Pond
Robert Post
Andrea Reid
Brent and Barbara Reid
The Rhoda and David Chase Foundation
Dr. Skip and Amy Sands
Christine Schumacher and Hal Hess
Lori and Richard Turbe

Taking on Children's Cancer from Every Direction *(cont.)*

The LLS Children's Initiative will bring precision medicine to children with cancer and ensure they have access to care.

Driving New Breakthroughs Faster

LLS is more than doubling our investment in pediatric cancer research grants worldwide. Our areas of focus include:

- Harnessing the immune system to fight cancer
- Identifying biomarkers to understand which patients will respond to certain therapies
- Overcoming treatment resistance
- Improving detection of cancer cells left after treatment that can lead to relapse
- Mitigating long-term treatment effects, such as cardiotoxicity and infertility

Further, LLS has undertaken an unprecedented collaboration to launch the first global precision medicine clinical trial for pediatric acute leukemia, called LLS PedAL. Building upon our successful Beat AML® Master Clinical Trial, LLS will unite physicians, scientists, regulators, advocacy organizations, pharmaceutical and biotechnology companies and others to change the paradigm of treatment through a precision medicine approach that puts pediatric patients first. Together, we will create a single set of pediatric cancer data that will be made available to researchers worldwide, identify and validate underlying molecular drivers of disease, and match patients with relapsed acute leukemia to the most promising treatments based on their unique tumor biology. The goal is to test multiple targeted therapies simultaneously at up to 200 clinical sites worldwide, with an anticipated opening in 2020.

Ensuring Access to the Best Care Possible

Because new breakthroughs are beneficial only if patients can access them, we are expanding our trusted education and support services—including resources for children and young adults with cancer and financial assistance programs—to help more patients, parents and caregivers navigate cancer treatments and access quality care. LLS is dedicated to helping children and families cope with the financial, emotional and psychological impact of a cancer diagnosis through our comprehensive array of free information, education and support.

Meanwhile, our policy and advocacy efforts focus on breaking down barriers to care and accelerating the development of new cancer treatments. LLS is co-chairing the Policy Committee of the Alliance for Childhood Cancer, a coalition of more than 25 advocacy groups and professional organizations. Through our work with the coalition, we played an instrumental role in the enactment of The Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, the most comprehensive federal childhood cancer legislation ever introduced.





Myrrah,
leukemia survivor

“I was inspired by past LLS Career Development Program awardees, many of whom are now leaders in the field. This award from LLS provides a tremendous boost to our research.”

— **G. Greg Wang, PhD, University of North Carolina Lineberger Comprehensive Cancer Center**

Dr. Wang is using a cutting edge gene-editing tool called CRISPR, combined with genetic profiling, to understand how a particular mutation called DNMT3A leads to the development of AML. With these insights, researchers can develop innovative new treatment strategies.





Accelerating Cures

Leading the Way to Cures

Our growing understanding of the genetic underpinnings of blood cancer is breaking new ground in cancer treatment and care. By supporting the full spectrum of research, from basic, laboratory-based science to large-scale clinical trials, LLS is at the forefront of the fight to cure cancer. At the same time, we're working tirelessly to ensure that treatment advances reach blood cancer patients. LLS is redoubling efforts to connect patients to clinical trials, which are critical avenues to improving access to care and discovering breakthroughs. Further, our Office of Public Policy works to increase research funding at the National Institutes of Health (NIH) and other federal agencies, accelerate FDA approval processes while still protecting patient safety, and promote patient-focused drug development that prioritizes patients' needs and concerns.

Investing in Pioneering Research

LLS is the largest nonprofit funder of blood cancer research. In 2019, we dedicated \$47.4 million to support scientific grants, including 106 new grants awarded to researchers across the globe. With more than 35 new Career Development Program grants, we continue to bolster the early careers of scientists. Our support of promising young scientists has produced three Nobel Prize winners, more than 15 National Academy of Sciences members and more than 10 department chairs of major cancer centers.

LLS invested \$7 million of our 2019 research budget in our Therapy Acceleration Program® (TAP), a venture philanthropy model through which we partner with biotech and academic institutions to advance promising novel therapies. New TAP partners include industry leaders such as Forty Seven, Inc., Sutro Biopharma, X4 Pharmaceuticals, Inc. and Verastem Oncology. Since 2017, three TAP-supported treatments were approved by the FDA.

Collaborating for Cures

LLS is driving innovative multi-year partnerships to maximize our research investment, including:

- A **\$1.8 million partnership** with the Snowdome Foundation and Australia's Leukaemia Foundation to support leading blood cancer research projects in Australia
- A **\$6.75 million collaboration** between LLS, The Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group to boost critical discovery research by seasoned investigators
- A **\$4 million partnership** with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) to accelerate global immunotherapy and prevention research
- A **\$1.5 million partnership** with the RUNX1 Foundation to advance better treatments for RUNX1 familial platelet disorder

Accelerating Cures *(cont.)*

Championing Immunotherapy

Our more than 20-year investment in CAR T-cell immunotherapy has paid off with two approved treatments for children and young adults with acute lymphoblastic leukemia (ALL) and adults with certain highly lethal lymphomas who have exhausted all other treatment options. Remarkably, many patients remain free of disease years after a single CAR T-cell dose. Today, we are funding the next generation of this game changing approach:

- **Helen Heslop, MD, Baylor College of Medicine**, is driving new immunotherapies for leukemia, lymphoma and myeloma. Her visionary team is maximizing approved CAR T-cell immunotherapies and developing “off the shelf” CAR-Ts that use cells from donors instead of patients to reduce production time.
- **Jianhua Yu, PhD, City of Hope**, is combining CAR-T and bispecific antibodies, two living drugs that launch persistent immune responses against cancer cells, to treat myeloma.

Based on the success in blood cancer, researchers are investigating applications in solid tumors, including lung, breast, colon and prostate cancer.

Outsmarting Cancer with Precision Medicine

LLS is unifying goals among science, industry, cancer centers, regulators, philanthropists and patients to revolutionize cancer treatment through precision medicine. Our Beat AML Master Clinical Trial is a case in point. Launched in 2016, the Beat AML Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to identify each AML patient’s cancer-driving genetic mutations, and then matches patients to the most promising targeted treatment within a rapid timeframe. More than 760 patients have been screened in 11 study arms at 16 cancer centers across the country.

Other highlights include:

- **Robert Orlowski, MD, PhD, University of Texas MD Anderson Cancer Center**, and his colleagues are studying the unique molecular features of patients with myeloma precursor diseases, so treatment can be tailored to prevent progression to full-blown myeloma.
- **Ari Melnick, MD, Weill Cornell Medicine**, is advancing novel therapies for B-cell lymphomas that target specific epigenetic mechanisms, the switches that turn genes on or off and control cell behavior.
- **Craig Jordan, PhD, University of Colorado**, is leading a world-class team of researchers to eradicate cancer stem cells—the roots of disease—in patients with AML through personalized approaches. This work is supported by a matching fund from the University of Colorado Medical Center.



“LLS’s early and sustained research investment in CAR T-cell immunotherapy is the reason I am here today and able to cherish every moment with my daughter.”

— **Chuck Colletti, diagnosed with non-Hodgkin lymphoma in 2016**

This year, Chuck fundraised proudly for LLS through our Man & Woman of the Year campaign.

Driving Clinical Trial Innovation, Education and Enrollment

Understanding the Value of Clinical Trials


Without sufficient enrollment in clinical trials, new treatments cannot be approved, scientific knowledge stalls and patients cannot access potentially lifesaving therapies. But the landscape is complex and evolving rapidly. Patients and caregivers are often left to search for trials on their own, leaving them with more questions than answers. The process can be cumbersome for healthcare professionals, too. Clinical research in the era of precision medicine is homing in on smaller groups of patients with specific disease subtypes or characteristics. Too many trials fail to meet their goals because there are not enough patients enrolled. Clinical trials are not “last resort” options, but rather avenues to leading edge care. LLS is committed to connecting patients to clinical trials, funding groundbreaking clinical science and advocating for policies that put patients at the center of their care.

Improving Access and Participation

LLS continues to expand our Clinical Trial Support Center (CTSC), in which Clinical Trial Nurse Navigators—registered nurses with expertise in blood cancers—conduct comprehensive clinical trial searches and assist patients and caregivers throughout the entire clinical trial enrollment process. Together, LLS Clinical Trial Nurse Navigators and LLS Information Specialists—master’s level oncology professionals—work one-on-one with blood cancer patients and caregivers to help them become more active participants in their care and overcome barriers to enrolling in trials, including assistance with finances and lodging.

On average, it takes more than 30 interactions with a patient, their caregivers and healthcare professionals to help a patient enroll in a clinical trial. This year, LLS Clinical Trial Nurse Navigators had nearly 8,000 interactions with patients, caregivers and healthcare professionals, demonstrating the depth and breadth of our support.

With only about 5 percent of all adult cancer patients in the U.S. enrolling in clinical trials, LLS is helping to bridge this enrollment gap with our free, personalized clinical trial navigation for blood cancer patients and their families. Typically, 22 percent of patients who are assisted by the CTSC enroll in an appropriate clinical trial, showing the power of our in-depth support on the lives of patients.






“I was on a mission to stay alive. The treatment options at the time were few, lacked effectiveness and had difficult side effects. After enduring six different treatments over 12 years, I achieved a complete remission finally, thanks to a clinical trial for an LLS-supported CAR T-cell immunotherapy.”

— **Laurie Adami, diagnosed with non-Hodgkin lymphoma in 2006**


She has set the goal of participating in Team In Training’s Climb 2 Cure at Mount Everest Base Camp in spring 2020.

LLS offers a wide array of free education and support for patients, caregivers and healthcare professionals.

- LLS Clinical Trial Nurse Navigators
- LLS Information Specialists
- Weekly online chats
- Peer-to-peer support
- Online social network called LLS Patient Community
- Financial assistance
- Nutrition consultations
- Caregiver support
- Webcasts
- Videos
- Podcasts
- Information booklets
- Continuing Education/ Continuing Medical Education programs



Dr. Selma Chen-Kiang



Driving Clinical Trial Innovation, Education and Enrollment *(cont.)*

Looking Forward

Beginning in 2020, LLS will expand a dynamic collaboration with the American Society of Hematology (ASH) to provide more than 2,500 ASH member physicians in the U.S. and Canada with dedicated access to the CTSC, making it easier to refer patients to our personalized support. This collaboration builds upon a successful pilot program completed in 2018, which found that the CTSC helped physicians have informed discussions with their patients about clinical trials as a possible course of treatment.


LLS is also working to expand clinical trial access among blood cancer patients in underserved communities. Through our new research program, Impactful Medicine Providing Access to Clinical Trials (IMPACT), we aim to bring innovative clinical trials to patients served by community cancer centers, especially in rural or economically disadvantaged areas. By fostering partnerships between community-based oncologists and clinical trial leaders at major cancer centers, IMPACT will help patients access clinical trials in their communities and educate local physicians about advances in genomics and precision medicine. The goal of each IMPACT grant is to increase clinical trial participation among blood cancer patients served by community cancer centers by at least 20 percent over a five-year period.

Pioneering New Models

LLS funds research from bench to bedside through collaborations, venture philanthropy and grants. This year, we invested \$32 million of our research budget to support clinical trials, along with an additional \$10.5 million to operate our Beat AML Master Clinical Trial, for a total investment of \$42.5 million. Complementing our research agenda are policy and advocacy efforts that push for affordable clinical trial access and hold the FDA accountable for implementing clinical trial reforms enacted in the 21st Century Cures Act, including new rules on master trials.

LLS champions these pioneering models. Our Beat AML Master Clinical Trial demonstrates that personalized treatment using genomics can be assigned to patients based on their specific subtype in less than seven days. With its flexible, collaborative structure, the trial is testing several novel therapies in multiple study arms simultaneously. This patient-first trial design—developed with guidance from the FDA—has the potential to stand as a model for future cancer clinical trials. Now, LLS will bring our leadership in patient-centric clinical trials to pediatric acute leukemia and other blood cancers. We will also continue to ensure that patients' needs and preferences are at the forefront of drug development to pave the way for better care and cures in the future.

◀ LLS-funded researcher Selina Chen-Kiang, PhD, Weill Cornell Medicine, and her world-class team



“I was armed with so much information. When you have information, you feel empowered. Every day, we learned more and that helped Meaghan take ownership of her health. I’d encourage anyone going through a blood cancer diagnosis to reach out to LLS. There is such an incredible network of support, and it’s so much better when you have someone in your corner.”

— **Maura Kilner, a caregiver for her daughter Meaghan, who was diagnosed with Hodgkin lymphoma in 2017**

As a 2019 Honored Hero for Students of the Year, Meaghan inspired and motivated high school students in her community to raise funds for our mission.



Helping Patients Throughout Their Cancer Experience

Approximately every three minutes, someone in the U.S. is diagnosed with a blood cancer. When someone experiences the fear and uncertainty of a cancer diagnosis, we provide hope, guidance, education and support. LLS is dedicated to helping patients navigate their cancer treatments and access quality care.

Supporting Patients, Caregivers and Families

We are committed to patients, caregivers and families throughout their entire cancer experience. Here at LLS, we believe one-on-one support makes all the difference, so we offer a wide array of free resources to help patients find the support they need.


For more than two decades, LLS Information Specialists have been on the front lines of an ever-changing healthcare landscape, guiding patients and caregivers to our robust education and support services. Information Specialists are master's level oncology professionals who provide free, personalized assistance to patients, families and healthcare providers. They offer guidance through cancer treatment, assist with financial and social challenges, and give accurate, up-to-date disease, treatment and support information. Information Specialists also refer patients to LLS Clinical Trial Nurse Navigators as appropriate.

According to an independent evaluation that concluded in 2019, **86 percent of patients and caregivers said they felt more hopeful** and **83 percent said they felt more comfortable managing their or their loved one's diagnosis** after their first contact with an Information Specialist. This is an extraordinary testament to the impact of LLS's one-on-one support.

We offer a variety of ways for patients and caregivers to find connections and support. This year, LLS:

- Connected more than 1,500 volunteers with patients and caregivers diagnosed with the same disease through LLS's *Patti Robinson Kaufmann First Connection Program*
- Reached nearly 12,000 patients and caregivers registered on our online social network, LLS Patient Community
- Provided nearly 900 patients and caregivers with free, personalized nutrition consultations from our registered dietitian
- Distributed a new, comprehensive caregiver workbook in English and Spanish to 930 caregivers

Contact an Information Specialist for one-on-one support at **1.800.955.4572**, and by live chat or email via **www.LLS.org**.



“Volunteering with Myeloma Link gave me a way to heal from my cancer experience, while helping someone else in the process. A diagnosis is a stumbling block, but there is light at the end of the tunnel. For me, the support and education I received from LLS has been that light.”

— **Kelvin Yates, diagnosed with myeloma in 2014**

In addition to providing direct support to patients, Kelvin participates in Light The Night.

Helping Patients Throughout Their Cancer Experience *(cont.)*

Educating Patients, Caregivers and Healthcare Professionals

LLS is here to help patients, caregivers and healthcare professionals stay informed and current on the latest disease, treatment and survivorship information.

This year, LLS:

- Distributed more than 855,000 educational booklets and fact sheets about blood cancers and survivorship topics
- Educated more than 132,400 patients, caregivers, healthcare professionals and others through live web-based and local in-person programs
- Reached nearly 12,000 listeners through LLS podcasts, including *The Bloodline with LLS* for patients and caregivers, and *Treating Blood Cancers*, a new podcast for healthcare professionals

Investing in Health Services Research

LLS plans to boost our investment in health services research to understand and address concerns about quality of life and access to care during treatment and beyond.

LLS is pursuing research into:

- The financial burden of treatment
- The services survivors or caregivers might need
- The preferences patients have when weighing treatment options
- The late effects survivors might be experiencing

This year, LLS received a three-year grant to fund a new intervention study by Carma Bylund, PhD, University of Florida, and her research team that aims to improve family and healthcare communication among adults who care for a parent with blood cancer. This work builds upon in-depth qualitative research completed by Dr. Bylund and LLS in 2018, which identified unique communication issues faced by these caregivers, including conflicts with siblings in negotiating caregiving responsibilities and navigating role reversals. As part of the intervention study, new online resources will launch on www.LLS.org in the next year to help caregivers of parents practice open, healthy communication with their families, find reliable cancer information online and communicate effectively with healthcare teams. Both research studies were funded by the Carolan Research Institute.

SPOTLIGHT ON MYELOMA LINK

African Americans have twice the incidence of myeloma as white Americans. Recent studies show that African Americans are significantly less likely to receive the latest treatments, and are more likely to experience treatment delays. LLS is dedicated to connecting African American communities to free myeloma information and support and enhancing access to care and the latest treatments through our Myeloma Link program. In 2019, the program expanded from two to eight cities, reaching more than 10,000 patients, caregivers and healthcare providers through over 100 awareness and education programs. Myeloma Link is just one part of our efforts to address the needs of underserved communities. LLS has committed \$35.4 million in multi-year grants to accelerate impactful myeloma research to find cures.

Breaking Down Barriers to Care

LLS invests in research critical to achieving cancer treatment breakthroughs, which often requires decades of effort and financial support. While LLS is advancing efficient clinical trial designs and cost effective ways to produce groundbreaking treatments, we need to take action now to ensure that cancer patients can access lifesaving treatments.

Taking Bold Action for Patients

With the cost of cancer care skyrocketing, a growing portion of these costs is being shifted to patients. As a result, some patients are delaying or even forgoing treatment. Through our nationwide grassroots network of more than 50,000 active online volunteers, LLS works to break down barriers standing between patients and the care they need.

In 2017, LLS launched our Cost of Cancer Care Initiative with aggressive, yet feasible cost-cutting ideas that would save money without sacrificing quality care. We shared our ideas with stakeholders across the healthcare ecosystem because we believe all players need to do their part to put patients first.

Since then, our Office of Public Policy has made significant progress on many fronts, including helping to advance reforms that level the playing field for lower-cost biosimilar versions of costly drugs. This year, we continued the momentum by putting forward 31 policy recommendations in March.

Six months later, we saw progress on 75 percent of these recommendations, including:

- Bi-partisan support for proposals to lower out-of-pocket costs, especially for those enrolled in Medicare Part D
- Measures under consideration to promote value-based payments, so that the cost of service reflects its value
- Measures adopted to increase marketplace competition, such as allowing generic drugmakers to introduce less expensive versions of costly drugs sooner

LLS also advocates for meaningful health insurance coverage, so that patients can afford the treatments they need. We advance solutions that uphold our core principles for meaningful coverage: guarantee access, promote affordability, ensure quality and encourage stability.

In particular, LLS calls upon lawmakers to limit the spread of short-term, limited duration health insurance plans, which pose risks to patients and consumers by requiring them to pay exorbitant costs. We pushed back against these plans through multifaceted efforts, urging members of Congress, governors, state legislators and insurance commissioners to take action to protect patients.

PROTECTING MEANINGFUL HEALTH INSURANCE

While legislators debated proposals that would roll back access to meaningful health insurance coverage, LLS took action.

MORE THAN
16,700 LETTERS
SENT BY
LLS ADVOCATES

MORE THAN
725 COMPLETED CALLS
MADE BY
LLS ADVOCATES

HUNDREDS
OF IN-PERSON MEETINGS
WITH POLICYMAKERS
CONDUCTED



“Policy change is needed to ensure that the patients I work with can access the care they need to live long and healthy lives. I’m proud to raise my voice with LLS and speak out on behalf of patients and their families.”

— **Myra Davis-Alston, a passionate LLS volunteer advocate who brings her unique perspective as an oncology nurse to our policy and advocacy endeavors**

Breaking Down Barriers to Care *(cont.)*

While we fight the rising cost of cancer care through our policy and advocacy endeavors, we know patients and caregivers need help now. We provide an array of financial assistance programs to help with cancer-related expenses.

Making a Difference

Through our financial assistance programs, we help patients and families navigate difficulties with insurance and co-pay burdens and cope with the often daunting financial challenges of cancer treatment. This year, LLS expanded the financial support we provide through two new programs to help blood cancer patients and their families when they need it most.

- The **LLS Urgent Need Program**, established in partnership with “Moppie’s Love,” is available to help pediatric and young adult blood cancer patients, or adult blood cancer patients enrolled in clinical trials, who are in acute financial need. The program provides a \$500 grant to assist with non-medical expenses, including utilities, rent, mortgage, food, lodging, dental care, child care, elder care and other essential needs.
- The **LLS Patient Aid Program** provides financial assistance to blood cancer patients, regardless of their financial circumstances. Eligible patients receive a \$100 stipend.

What patients and families are saying:

“Without your financial and moral support, I wouldn’t be alive today. You help put food on my table and hope in my heart.”

“LLS has been a wonderful help when a tough financial spot arose from our daughter’s long in-patient stay. The \$500 [from the LLS Urgent Need Program] helped with our rent.”

“Your program has been a saving grace for my parents. They planned for retirement and would have had everything wiped out had it not been for your service.”

LLS FY19 FINANCIAL SUPPORT BY THE NUMBERS

LLS PATIENT AID PROGRAM

More than **\$1.3 million** in assistance provided to more than **13,200** blood cancer patients

URGENT NEED PROGRAM

Nearly **\$1.2 million** total in assistance provided to more than **2,350** families

CO-PAY FINANCIAL ASSISTANCE

More than **\$97.1 million** provided in co-pay financial assistance supporting nearly **19,000** patients

SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM

More than **\$1.1 million** in assistance provided to more than **2,200** blood cancer patients to help with transportation and lodging-related expenses

Uncovering New Insights

Here at LLS, we believe no one should have to choose between seeking care and affording groceries or a mortgage. The cost of cancer care is becoming unsustainable for both cancer patients and the overall healthcare system. LLS is investing in more research to understand the financial burdens associated with the cost of blood cancer treatment and its long-term effects, as well as disparities in patients' access to the latest treatments. Leading edge LLS-funded research projects include:

- **Rena Conti, PhD, Associate Research Director of Biopharma & Public Policy at the Boston University Institute for Health System Innovation & Policy**, is leading a study to understand better the range of financial difficulties experienced by patients with multiple myeloma or chronic lymphocytic leukemia who are undergoing or have forgone treatment at National Cancer Institute Community Oncology Research Program (NCORP) Minority/Underserved Community Sites across the country. Dr. Conti is also a Dean's Research Scholar and Associate Professor of Markets, Public Policy and Law at the Boston University Questrom School of Business.
- **Stacie Dusetzina, PhD, Associate Professor of Health Policy and Ingram Associate Professor of Cancer Research at Vanderbilt**, is leading a two-year study jointly funded by LLS and The Commonwealth Fund on the impact of healthcare

costs on the behavior of senior patients enrolled in Medicare. Her research is examining the association between delaying or never filling specialty drug prescriptions and health outcomes related to the disease being treated.

In addition, we commissioned two studies by the actuarial firm, Milliman, examining the factors that are driving blood cancer costs within the healthcare system as well as the out-of-pocket cost burden that patients experience. The findings showed, for example, that treatment of acute leukemia among commercially insured patients cost the healthcare system more than \$800,000 on average in the first three years following a patient's diagnosis. For patients with Medicare coverage, those being treated for lymphoma spent as much as \$19,000 out-of-pocket on medical costs in the first year following their diagnosis, while those with myeloma spent \$24,000 on average in the first two years following diagnosis.

These extraordinary costs underscore the simple fact that meaningful insurance coverage is a necessity for virtually anyone in need of blood cancer treatment. The high cost of care is also a reminder that as we make advancements in the treatment of blood cancer, we must pursue policies that ensure those treatments are accessible to the patients who need them. To learn more about our Cost of Cancer Care Initiative, please visit www.LLS.org/cancercost.

▼ LLS-funded researcher Dr. Rena Conti





DRIVING SUPPORT ACROSS THE COUNTRY

For generations of families and children, our signature fundraising campaigns have helped LLS find cures and ensure access to treatments for blood cancer patients nationwide. We are inspiring people across the country to run, hike, walk, sail, build teams and gain lifelong learning skills while raising funds to drive forward our mission. This year, LLS is featured once again in *The Chronicle of Philanthropy's* "America's Favorite Charities," and jumped from number 61 last year to number 39 in 2019, showcasing one of the highest growth rates in charitable contributions (34 percent). Among charities with a health focus, LLS is ranked sixth on the list.

For more than 30 years, LLS has been a pioneer in creating unique and innovative peer-to-peer fundraising campaigns.

The Leukemia Cup Regatta, a thrilling series of events that combines the joy of on-water sports with the important task of raising money to cure cancer, commenced in 1988. Skippers and their crews participate in more than 45 regattas nationwide.

LLS's flagship campaign **Team In Training®** was formed in 1988. From there, Team In Training has gone on to set the standard for endurance sports fundraising programs worldwide. More than 650,000 teammates have run, walked, hiked, cycled, climbed and competed in triathlons.

Man & Woman of the Year, a philanthropic competition, launched in 1990. Now taking place in nearly 100 communities across the country, the campaign brings together a passionate group of individuals and their teams for an exciting 10-week philanthropic competition to win the title of "Man or Woman of the Year."



Since 1993, children have experienced the satisfaction that comes from helping others by fundraising in honor of local, school-aged patients battling blood cancers. More than 14.5 million students, families and educators in 27,000 schools across the U.S. participate annually in programs, such as **Pennies for Patients**.

Light The Night® kicked off nationwide in 1999 and is now the fifth largest peer-to-peer fundraising program in the U.S. One million friends, families and co-workers gather together and bring light to the darkness of cancer, carrying illuminated lanterns in 140 inspirational evening walks to celebrate, honor or remember those touched by cancer.

New innovative fundraising campaign **Students of the Year** launched nationally in 2017 and is helping to foster committed young philanthropists and redefine what giving looks like in today's charity and community service environment.

LLS Lifestyle, initiated in 2017, is a new peer-to-peer fundraising platform that enables LLS supporters to get creative and start their own movement. In its inaugural year, participants turned their creative ideas into impactful fundraising activities in support of LLS.



BURLINGTON STORES, INC.

PARTNERING FOR PROGRESS TOWARD CURES

We are grateful to our partners and sponsors, who harness the power of their consumers, communities and employees to help fight blood cancers. Some of our top partners include:

Burlington Stores, Inc.

For the past 17 years, LLS has partnered with Burlington to host an in-store point-of-sale campaign that raises funds to further the LLS mission. Through this campaign, Burlington associates ask customers to donate \$1 or more at checkout to raise critical funds for research and patient support that help to save lives and bring smiles to the faces of children and families impacted by blood cancer. Burlington is our number one National Corporate Partner and Honored Friend, having raised more than \$37 million since 2002.

United Food and Commercial Workers Union (UFCW)

UFCW takes great pride in the longstanding partnership with LLS—37 years and more than \$90 million raised. The Labor Against Cancer initiative, launched in 2017, features a fundraising drive among members, retail campaigns and walking to end cancer with LLS's Light The Night, and represents an unprecedented effort to mobilize more than one million members and their families to build awareness and help raise funds.

Walgreens

Walgreens has been collaborating with and supporting LLS since 2016, providing education and resources for patients and their families who are living with blood cancer; this includes training and certification for specialty pharmacists and sponsoring our Blood Cancer Conferences. Walgreens' commitment extends far beyond patient and professional education. Last year, more than 6,500 Walgreens stores participated in fundraisers that raised \$2.6 million for LLS. Nearly 250 Walgreens teams around the country also participated in Light The Night.



Subaru

Together, Subaru retailers and local LLS staff deliver co-branded blankets and arts and crafts kits to adults and children fighting cancer along with “message of hope” cards signed by visitors to the retailers, offering words of encouragement and hope. Since 2016, LLS and Subaru have donated more than 148,000 blankets and 21,500 arts and crafts kits and reached nearly 150,000 patients in more than 780 hospitals, with the help of more than 540 Subaru retailers nationwide.

WAWA

Wawa and The Wawa Foundation are proud partners of LLS, holding in-store customer engagement fundraising each year to benefit Light The Night. In 2018, The Wawa Foundation committed to presenting-level sponsorship support in both Philadelphia and Washington, D.C. Additionally, the Foundation recently announced a \$1 million grant to The LLS Children’s Initiative to accelerate new and better treatments for pediatric blood cancers.

We thank the following longstanding partners for their steadfast commitment to LLS’s mission, supporting patient education, support services, advocacy and policy initiatives, our cutting edge research and fundraising campaigns:

Genentech
Since 1999

Celgene
Since 2001

Takeda
Since 2004

Pharmacyclics and Janssen
Since 2014



BEAT AML EVENT

KELLENYI FAMILY

MICHAEL TREINEN FOUNDATION

LYON FAMILY

RECOGNIZING OUR SUPPORTERS

Celebrating a Beat AML Victory

This year, LLS achieved a historic milestone: we met our ambitious fundraising goal of \$125 million for Beat AML. Donors, volunteers, supporters, Beat AML project leads, and LLS staff and leadership gathered to celebrate at two festive events: one in New York City and the other in San Francisco.

Hosting the events, Dr. Louis DeGennaro declared: “I call it a victory, because that is exactly what this is. We took on the challenge of leading a global initiative to find new treatments for a cancer that had not seen real progress in four decades. And because of all of you, we are victorious and will continue to fight this battle.”

The evenings highlighted how this, the first-ever capital campaign held by LLS, is a real game-changer—and not just for LLS but for the entire medical field. With our donors and partners, Beat AML advanced novel science and validated a revolutionary master clinical trial model that puts patients at the center of the research paradigm.

And, it opened the door for further advances in acute myeloid leukemia through continued Beat AML efforts, as well as the launch of The LLS Children’s Initiative.

Beat AML demonstrates the power of philanthropy at LLS.

Honoring the life and contribution of campaign vice-chair, John Kellenyi, Michael Copley, national chair, spoke of John’s impact. “The campaign would not have been the same without John,” said Michael. “He was the most amazing fundraiser, friend and human being. John took tremendous pride in knowing what he did furthered the LLS mission by improving and saving the lives of patients.”

From left: Cristina Kellenyi, Dr. Louis DeGennaro, Teresita Kellenyi, Michael Copley

“Our son Michael passed away in 2008 from AML and our goal is to support better treatments and results through the work of LLS and the Beat AML initiative. We want people who are diagnosed with AML to know that there is hope!”

— Kelly Treinen, The Michael Treinen Foundation, Noblesville, Indiana

“After losing our beloved son and brother Robert Lyon to AML in 2007, we dedicated our family foundation to supporting AML research to ensure that those facing



**LYNNE O'BRIEN AND
EVELYN BATA, PHD**



WOMEN CURING CANCER

©Jeanine L. Cummins



ANBINDER FAMILY



TROVATO FAMILY

the same diagnosis have far better odds at beating the disease. With the Beat AML initiative in full swing, the Lyon Family Foundation is even more focused on disrupting the current trajectory for these patients and seeing treatment change at a really rapid rate!”

— Lyon Family, Chicago, Illinois

“Women are changing the world through our growing leadership and strategic philanthropy. Collectively we’re going to have a greater impact than alone. That is why we have launched Women Curing Cancer, a community of women seeking to accelerate cancer cures, especially for children. We believe the way to cure cancer is to identify the best and brightest researchers and support the most innovative and promising projects. Together, we can drive incredible progress in science and medicine.”

— Lynne O’Brien and Evelyn Bata, PhD, Co-founders, Women Curing Cancer

Women Curing Cancer is a group of women leaders who are partnering with LLS to accelerate cancer cures.

“When I was diagnosed with CLL in 2001, I knew nothing about the disease or what it meant for my future. LLS provided the information I requested and put me in touch with my local chapter. That was

the beginning of a long and wonderful relationship. Wanting to give back to LLS, I became a volunteer and later Trustee for the chapter and formed a Family & Friends team to participate in the annual Light The Night walk. My brother and sister-in-law, Steve and Maddy, have been incredibly generous over the years with their own philanthropy to LLS. We want our help to continue after us, so both Paul and I have named LLS in our will. Steve and Maddy established an annuity with LLS that will serve the same purpose.”

— Helen Anbinder, New York

“My journey with LLS began in 2008 right after going through the frightening diagnosis of non-Hodgkin lymphoma. I heard about LLS’s Team in Training and I felt I could use my personal experience to raise money for a more than worthy cause. I later served on the Long Island Chapter’s Board of Trustees and learned about the funding needed for research, which is the only way to find a cure for all blood cancers. I decided to make a personal gift directly to research while also continuing my fundraising crusade for Team In Training. LLS has changed my life and will always be a part of my life as well as my family’s.”

— Gary Trovato, Long Island

Acknowledging Our Extraordinary Volunteers

Our lifesaving work would not be possible without volunteers. Each day, volunteers across the country give their time and talent to activities that support our mission. Their efforts are game changing: they provide the leadership, big ideas and dedication we need to beat cancer.

LLS volunteers are part of a diverse and vibrant community of supporters who represent all walks of life and bring different experiences and passions to drive forward our mission. With countless ways to engage, from raising critical funds, to advocating for lifesaving policies, to providing support to those impacted by cancer, our volunteers are truly making a difference.

Since we started in 1949, the partnerships between volunteers and staff have been at the heart of our quest to find cancer cures. That's why LLS is committed to recognizing and engaging volunteers who support every facet of our organization.

This year, LLS launched Volunteers in Action (VIA), a new online and mobile platform that will help us do exactly that. VIA empowers volunteers throughout their journey with LLS, connecting them to the tools, resources and people they need to create impact. With VIA, volunteers can see the impact of their time, sign up for the latest opportunities and interact with staff and other volunteers who share their interests.

If you volunteer with LLS or have in the past, **THANK YOU** for your incredible partnership. You inspire us to work tirelessly toward our mission every single day.

If beating cancer is in your blood, we have a rewarding volunteer opportunity for you – whatever your interests, skills or time commitments.

Learn more at www.volunteerLLS.org.



“We’ve met amazing people through LLS and built so many relationships, especially with Man & Woman of the Year candidates—some of whom are survivors themselves. And we’ve met others who don’t have a connection, but just want to help. Becoming part of the LLS community has been such an amazing experience for our family.”

— **Rachel Dacanay-Smith, mother of Lucia, who was diagnosed with acute promyelocytic leukemia in 2018**

After enduring an intense, nine-month treatment regimen, Lucia’s cancer went into complete remission. As the 2019 Girl of the Year for LLS’s National Capital Area Chapter, Lucia inspired Man & Woman of the Year candidates to raise significant funds and awareness.

FINANCIALS

Independent Auditors' Report

The Board of Directors The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2019, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on

the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2019, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Emphasis of Matter

As discussed in note 1(t) to the consolidated financial statements, in 2019 The Leukemia & Lymphoma Society, Inc. adopted new accounting guidance,

Accounting Standards Update 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities*. Our opinion is not modified with respect to this matter.

Report on Summarized Comparative Information

We have previously audited the The Leukemia & Lymphoma Society, Inc. 2018 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated November 7, 2018. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2018 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived before the adjustments to adopt Accounting Standards Update 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities*. As part of our audit of the 2019 consolidated financial statements, we also audited the adjustments described in note 1(t) that were applied to adopt Accounting Standards Update 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities* retrospectively in the 2018 consolidated financial statements. In our opinion, such adjustments are appropriate and have been properly applied.

KPMG LLP

November 5, 2019

Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2019 (with comparative amounts at June 30, 2018) (In thousands)

Assets	<u>2019</u>	<u>2018</u>
Cash and cash equivalents	\$ 24,735	27,628
Prepaid expenses and other assets	4,653	2,767
Contribution and other receivables, net (note 7)	15,489	32,255
Investments (note 4)	407,903	319,662
Fixed assets, net (note 10)	<u>9,161</u>	<u>8,614</u>
Total assets	<u>\$ 461,941</u>	<u>390,926</u>
 Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 23,487	21,907
Deferred revenue (note 8)	13,739	16,243
Awards and grants payable (note 2)	50,974	51,673
Co-Pay assistance payable (note 3)	94,957	54,696
Other long-term liabilities (note 11)	<u>4,715</u>	<u>3,835</u>
Total liabilities	<u>187,872</u>	<u>148,354</u>
Commitments and contingencies (notes 2, 3, 12 and 14)		
Net assets:		
Without donor restrictions	178,099	149,199
With donor restrictions (notes 3 and 6)	<u>95,970</u>	<u>93,373</u>
Total net assets	<u>274,069</u>	<u>242,572</u>
Total liabilities and net assets	<u>\$ 461,941</u>	<u>390,926</u>

See accompanying notes to consolidated financial statements.

Consolidated Statement of Activities

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019
(with summarized totals for the year ended June 30, 2018) (In thousands)

	Without Donor Restrictions	With Donor Restrictions	Total	
			2019	2018
Operating revenue:				
Contributions	\$ 273,691	20,832	294,523	282,108
Less direct donor benefit costs	(29,624)	—	(29,624)	(29,198)
Net campaign contributions	244,067	20,832	264,899	252,910
Co-Pay contributions (note 3)	—	90,930	90,930	159,851
Therapy Acceleration Program contractual return	4,495	—	4,495	3,855
Service revenue	14,936	—	14,936	9,230
Donated services, goods and media (note 9)	11,987	—	11,987	7,715
Legacies and other revenue	6,721	13,187	19,908	11,018
Net interest and dividend income	5,265	1,921	7,186	4,316
Net assets released from restrictions:				
Co-Pay assistance (note 3)	102,057	(102,057)	—	—
Satisfaction of other donor restrictions	22,456	(22,456)	—	—
Total operating revenue	411,984	2,357	414,341	448,895
Operating expenses:				
Program services:				
Research	71,119	—	71,119	66,865
Patient and community service	153,138	—	153,138	162,707
Public health education	45,130	—	45,130	39,557
Professional education	14,500	—	14,500	16,425
Total program services	283,887	—	283,887	285,554
Supporting services:				
Management and general	54,258	—	54,258	44,698
Fund raising	49,101	—	49,101	42,342
Total supporting services	103,359	—	103,359	87,040
Total operating expenses	387,246	—	387,246	372,594
Change in net assets from operating activities	24,738	2,357	27,095	76,301
Foreign currency translation adjustment and other	(38)	1	(37)	(99)
Net increase in fair value of investments	4,200	239	4,439	7,060
Change in net assets	28,900	2,597	31,497	83,262
Net Assets:				
Beginning of period	149,199	93,373	242,572	159,310
End of period	\$ 178,099	95,970	274,069	242,572

See accompanying notes to consolidated financial statements.

Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019 (with comparative totals for the year ended June 30, 2018) (In thousands)

	Program Services				Supporting Services			Year ended		Direct donor benefit costs	
	Research	Patient and community service	Public health education	Professional education	Management and general	Fund raising	Total	June 30,	June 30,	2019	2018
								2019	2018	2019	2018
Awards and grants	\$ 45,687	—	—	—	—	—	45,687	44,517	—	—	—
Therapy acceleration program	2,433	—	—	—	—	—	2,433	5,834	—	—	—
Clinical trial	10,468	—	—	—	—	—	10,468	5,899	—	—	—
Financial aid to patients	—	4,228	—	—	—	—	4,228	2,007	—	—	—
Co-Pay assistance	—	97,151	—	—	—	—	97,151	108,442	—	—	—
Co-Pay processing fees	—	4,088	—	—	—	—	4,088	6,571	—	—	—
Donated services, goods and media	628	2,572	3,786	222	415	4,364	7,208	11,987	—	—	—
Salaries and employee benefits and taxes	4,969	27,744	22,993	8,505	30,256	22,674	64,211	117,141	108,350	—	—
Professional fees	4,755	4,803	4,606	2,042	7,441	4,514	16,206	28,161	23,558	4,468	4,395
Printing, advertising, and supplies	133	3,611	5,809	1,046	2,561	9,156	10,599	22,316	18,516	6,725	6,286
Occupancy, telephone and insurance	222	3,147	2,775	908	2,596	2,467	7,052	12,115	11,731	—	—
Travel and meetings	614	2,221	2,056	1,005	1,358	1,426	5,896	8,680	7,267	16,463	16,043
Equipment rentals and maintenance	1,005	739	336	136	4,511	1,238	2,216	7,965	5,442	—	—
Postage and shipping	23	1,408	1,693	229	581	2,279	3,353	6,213	7,040	—	—
Miscellaneous	174	1,285	949	368	602	871	2,776	4,249	4,206	1,968	2,474
Depreciation and amortization	8	141	127	39	3,937	112	315	4,364	5,499	—	—
Total expenses	\$ 71,119	153,138	45,130	14,500	54,258	49,101	283,887	387,246	372,594	29,624	29,198

See accompanying notes to consolidated financial statements.

Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (In thousands)

	<u>2019</u>	<u>2018</u>
Cash flows from operating activities:		
Change in net assets	\$ 31,497	83,262
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Net increase in fair value of investments	(3,497)	(7,341)
Depreciation and amortization	4,364	5,499
Provision for uncollectible accounts	396	(630)
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	(1,886)	846
Contributions and other receivables, net	16,370	(13,840)
Accounts payable and accrued expenses	1,580	196
Other long-term liabilities	880	668
Deferred revenue	(2,504)	2,215
Awards and grants payable	(699)	(12,379)
Co-Pay assistance payable	<u>40,261</u>	<u>34,625</u>
Net cash provided by operating activities	<u>86,762</u>	<u>93,121</u>
Cash flows from investing activities:		
Purchases of fixed assets	(4,911)	(3,994)
Purchases of long-term investments	(92,600)	(150,533)
Sales of investments	<u>7,856</u>	<u>47,633</u>
Net cash used in investing activities	<u>(89,655)</u>	<u>(106,894)</u>
Net decrease in cash and cash equivalents	(2,893)	(13,773)
Cash and cash equivalents at beginning of period	<u>27,628</u>	<u>41,401</u>
Cash and cash equivalents at end of period	<u>\$ 24,735</u>	<u>27,628</u>

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

1) Organization and Summary of Significant Accounting Policies

(a) Organization

The Leukemia & Lymphoma Society, Inc. (LLS) is the world's largest voluntary health agency dedicated to finding cures for blood cancers and providing services to blood cancer patients, their families, and caregivers. LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today's most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

(b) Principles of Consolidation

The accompanying consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty six chapters in the United States, and LLS's not for profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS. Effective February 8, 2018, PPCS was dissolved. All significant intercompany and intra LLS accounts and transactions have been eliminated in consolidation.

(c) Tax-Exempt Status

LLS, LLSRP and LLSRF qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS and its related entities recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities that recognized any unrelated business income tax liability for the years ended June 30, 2019 and 2018.

(d) Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS's management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include allocation of expenses, and valuation of donated goods, services and media. Actual results could differ from those estimates.

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

(e) Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS's principal source of revenue is contributions by the general public. Accordingly, LLS's operations are dependent upon individual contributions, that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the Co Pay program in 2019 and 2018 was funded by six donors, respectively. In addition, the Beat AML Master Trial was primarily funded by seven donors in 2019 and 2018, respectively.

(f) Summarized Financial Information

The consolidated financial statements are presented with 2018 summarized information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2018 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS's 2018 consolidated financial statements from which the summarized information was derived.

(g) Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2019 through November 5, 2019, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

(h) Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into two net asset categories as follows:

Net assets without donor restrictions: Consist of funds that are fully available, at the discretion of LLS's Board of Directors, for LLS to utilize in any of its programs or supporting services.

Net assets with donor restrictions: Consist of funds that are restricted by donors for a specific time period and/or purpose. Also included in this category are net assets subject to donor imposed restrictions, which stipulate that the principal be maintained by LLS, but permits LLS to expend part or all of the income and gains derived there from. Expirations of restrictions are reported as net assets released from restrictions when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board approved spending policy (note 6).

Revenue and gains and losses on investments and other assets and liabilities are reported as changes in net assets without restrictions unless limited by explicit donor imposed restrictions or by law. Expenses are reported as decreases in net assets without donor restrictions.

LLS delineates changes in net assets without donor restrictions as operating or non operating activities. Operating activities include all operating revenues and expenses that are an integral part of its programs and supporting activities and net assets released from donor restrictions to support operating expenditures. The measure of operations include support for operating activities from both with donor restrictions and without donor restrictions designated for long term investment according to LLS's spending rate policy (note 6). Non operating activities include changes in fair value of investments and foreign currency translation adjustment and other nonrecurring items.

(i) Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

(j) Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted or published prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs other than quoted or published prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value (NAV) per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

(k) Contributions, Grants and Deferred Revenue

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as revenues with donor restrictions. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statement of activities as net assets released from restrictions.

Contributions expected to be received after one year are discounted at a risk adjusted rate of return. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor imposed restrictions, if any, on the contributions.

Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(l) Service Revenue

Service revenue is accounted for as an exchange transaction whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

(m) Donated Goods and Services

LLS has determined that certain of the donated goods and services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed goods was determined based on fair market value estimates. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These goods and services are recognized as revenue and expense (note 9).

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

(n) Donated Media

LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSA's (note 9).

(o) Cash Equivalents

Cash equivalents consist of short term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

(p) Investments

Investments are stated at fair value based upon quoted or published market prices, except for the fair values of alternative investments which are based on NAVs provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

(q) Fixed Assets and Depreciation

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

(r) Other Long Term Liabilities

Other long term liabilities represent LLS's liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 11), straight line rent of office leases (note 12), and capital leases.

(s) Professional Fees

Professional fees included in the consolidated financial statements principally include professional fund raising fees, contracted software development, and legal and auditing fees.

(t) Adopted Accounting Pronouncements

The FASB issued Accounting Standards Update (ASU) 2016 14, Presentation of Financial Statements of Not for Profit Entities, which among other things, changes how not for profit entities report net asset classes, expenses and liquidity in their financial statements. LLS adopted the main provisions of this guidance which include, the reduction of the number of net asset classes from three to two: with donor restrictions, previously reported as temporally restricted net assets of \$90,221 and permanently restrictions net assets of \$3,152, in 2018, and without donor restrictions, previously reported as unrestricted net assets of \$149,199, in 2018; the presentation of expenses by their function and their natural classification in one location; and quantitative and qualitative information about the management of liquid resources and availability of financial assets to meet cash needs within one year of the balance sheet date.

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

(u) Upcoming Accounting Standards

ASU No. 2014 09, *Revenue from Contract with Customers (Topic 606)* – This ASU, effective for LLS's fiscal year ending June 30, 2020, will require LLS to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which LLS expects to be entitled in exchange for those goods or services. Management is evaluating the effect ASU 2014 09 will have on its consolidated financial statements.

ASU No. 2018 08, *Not for Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contribution Received and Contributions Made* – This ASU, effective for the LLS's fiscal year ending June 30, 2020, is intended to clarify how entities determine whether to account for a transfer of assets (or a reduction, settlement, or cancellation of a liability) as an exchange transaction or a contribution based on whether commensurate value has been received or transferred. The new guidance also clarifies that a contribution is conditional if the agreement includes both a barrier that must be overcome for the recipient to be entitled to the assets transferred and a right of return for the transferred assets or a right of release of a promisor's obligation to transfer assets. Management is evaluating the effect ASU 2018 08 will have on its consolidated financial statements.

ASU No. 2016 02, *Leases (Topic 842)* – This guidance, effective for LLS's fiscal year ending June 30, 2022, requires a lessee to recognize a right of use asset and a lease liability, initially measured at the present value of the lease payments on the consolidated balance sheet and disclosing key information about leasing arrangements. Management is evaluating the effect ASU 2016 02 will have on its consolidated financial statements.

(v) Functional Allocation of Expense

The costs of providing the various programs and other activities have been summarized on a functional basis. Accordingly certain costs attributable to more than one program or supporting services function are allocated using cost allocation methods such as square footage and estimate of time and effort.

LLS allocates expenses relating to the operation and maintenance of plant and depreciation using building square footage based on functional use.

2) Research

LLS has various activities that are utilized to carry out its mission as presented below:

Research:

Awards and Grants: Awards and grants for research are approved by LLS's Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS's Board of Directors. LLS has multi year grant commitments of \$39,093 at June 30, 2019, which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of \$50,974 and \$51,673 at June 30, 2019 and 2018, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately \$1,665 and \$984 as of June 30, 2019 and 2018, respectively, have been netted against awards and grants expense.

Therapy Acceleration Program (TAP):

TAP is LLS's strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug enabling studies and clinical stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS's Board of Directors. LLS has contract commitments of \$14,471 and \$12,745 at June 30, 2019 and 2018, respectively, that are conditioned upon future events and, accordingly, are not recorded. Grant refunds of approximately \$320 and \$591 as of June 30, 2019 and June 30, 2018, respectively have been netted against therapy acceleration program contractual return.

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows:

Year ending June 30:		
2020	\$	30,206
2021		17,868
2022		5,323
2023 and thereafter		167
Total	\$	<u>53,564</u>

For the year ended June 30, 2019 and 2018, LLS received \$4,495, and \$3,855 of TAP contractual returns from various TAP contracts.

3) Co-Pay Assistance Program

Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance Co-Pay obligations for prescription medications or private/public health insurance premiums. Revenue is recognized when donations are received while expenses are recognized as patient applications are approved for participation according to program criteria and on availability of funding. The Co-Pay Assistance payable of \$94,957 and \$54,696 has been established based on approved patient applications received through June 30, 2019 and 2018, respectively. At June 30, 2019, net assets with donor restrictions include \$43,279 received through June 30, 2019, which are available for expenditure and are intended to be awarded in future periods.

The following summarizes the activities of the Co-Pay Assistance program as of June 30, 2019.

	<u>June 30, 2019</u>	<u>June 30, 2018</u>
Beginning balance	\$ 52,528	8,148
Contributions	90,930	159,851
Investment Gains	1,878	326
Amount expended during the year:		
Direct assistance to patients	(97,151)	(108,442)
Other expenses incurred and reimbursed under the contract	<u>(4,906)</u>	<u>(7,355)</u>
Amounts available for expenditures in subsequent periods	<u>\$ 43,279</u>	<u>52,528</u>

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

4) Investments

The following tables present LLS's fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2019 and June 30, 2018:

	<u>2019</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Money market funds and cash	\$ 239,287	239,287	—	—
Fixed income:				
Corporate bonds	63,201	63,201	—	—
Equities:				
Large cap equity	39,198	39,198	—	—
International equity	26,695	26,695	—	—
Small/mid cap equity	26,273	26,273	—	—
Commodities	4,935	4,935	—	—
	<u>399,589</u>	<u>\$ 399,589</u>	<u>—</u>	<u>—</u>
Investments reported at NAV:				
Multi strategy hedge funds	<u>8,314</u>			
	<u>\$ 407,903</u>			

	<u>2018</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Money market funds and cash	\$ 158,371	158,371	—	—
Fixed income:				
Corporate bonds	56,758	56,758	—	—
Government securities and other	849	849	—	—
Equities:				
Large cap equity	35,644	35,644	—	—
International equity	33,437	33,437	—	—
Small/mid cap equity	22,872	22,872	—	—
Commodities	3,665	3,665	—	—
	<u>311,596</u>	<u>\$ 311,596</u>	<u>—</u>	<u>—</u>
Investments reported at NAV:				
Multi strategy hedge funds	<u>8,066</u>			
	<u>\$ 319,662</u>			

Within the investment balance as of June 30, 2019 and June 30, 2018 are \$123,297 and \$89,492 restricted to Co-Pay, respectively.

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

LLS's alternative investments strategy:

Multi strategy hedge funds – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.

This strategy creates indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS's risk with respect to such transactions is limited to its capital balance in each investment.

LLS's alternative investments contain various redemption restrictions with required written notice ranging from 45–95 days. By contrast, all of LLS's nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2019 and 2018, the following table summarizes the redemption provisions for those investments reported at NAV:

	<u>2019</u>	<u>2018</u>
Redemption period:		
Monthly	\$ 1,600	—
Quarterly	4,000	6,380
Semi-Annual	1,000	—
Annual	<u>1,714</u>	<u>1,686</u>
Total	<u>\$ 8,314</u>	<u>8,066</u>

As of June 30, 2019 and 2018, LLS had no unfunded commitments on its alternative investments.

5) Financial Assets

LLS goal is to maintain financial assets to meet the requirements of all outstanding commitments, excluding Co-Pay, both current and conditional as well as a minimum of 25-50% of annual general expenditures. LLS considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures, excluding expenditures related to LLS Co-Pay Program. As part of LLS liquidity plan, excess cash is invested in short term investments, including money market accounts, fixed income and equities.

In addition to available financial assets, LLS operates with a balanced budget and anticipates collecting sufficient revenue to cover all general expenditures. Refer to the statement of cash flows, which identifies the sources and uses of LLS' cash and shows positive cash generated by operations for fiscal years 2019 and 2018.

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

The following represents LLS's financial assets as of June 30, 2019:

	2019
Financial assets at year end:	
Cash and cash equivalents	\$ 24,735
Contributions and other receivable	15,489
Investments	407,903
Total financial assets	<u>448,127</u>
Less amounts not available to be used within one year:	
Contributions and other receivable with donor restrictions not to be met in less than a year	9,485
Alternative investments with redemptions greater than 12 months	1,714
Equity holdings not expected to be redeemed	8,866
Restricted to support Co-Pay patients	138,538
Perpetual donor restriction	3,117
Total financial assets not available for use	<u>161,720</u>
Financial assets available to meet general expenditures within one year of the balance sheet date	<u>\$ 286,407</u>

6) Net assets with donor restrictions

Net assets with donor restrictions and the income earned are available for the following purposes at June 30, 2019 and 2018:

	2019	2018
Research	\$ 8,501	8,977
Patient and Community Service	4,544	4,609
Public Health Education	3,579	2,572
Professional Education	3,599	2,783
Beat AML Initiative	23,611	14,750
Children's Initiative	2,905	851
Beat AML Master Trial	5,623	6,144
Co-Pay	43,279	52,528
Other	329	159
Total net assets with donor restriction	<u>\$ 95,970</u>	<u>93,373</u>

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act, which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2019 and 2018 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS's overall investment strategy.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2019 and 2018:

	<u>2019</u>	<u>2018</u>
Endowment net assets at July 1	\$ 6,577	6,282
Investment income	304	551
Foreign currency translation adjustment	2	(7)
Appropriation for expenditure	<u>(303)</u>	<u>(249)</u>
Endowment net assets at June 30	<u>\$ 6,580</u>	<u>6,577</u>

7) Contribution and other receivables

LLS's contribution and other receivables at June 30, 2019 and June 30, 2018 consist of unconditional promises to give, receivables associated with service revenue, and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met.

Contributions and other receivables consist of the following:

	<u>2019</u>	<u>2018</u>
Campaign contributions	\$ 2,909	1,539
Other restricted contributions	11,627	15,266
Co-Pay contributions	—	15,100
Service revenue	<u>953</u>	<u>350</u>
Total	<u>\$ 15,489</u>	<u>32,255</u>

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate. Amounts are scheduled to be received as follows:

	<u>2019</u>	<u>2018</u>
Less than one year	\$ 11,027	24,400
One to five years	<u>6,287</u>	<u>10,076</u>
	17,314	34,476
Less:		
Allowance for uncollectible accounts	(641)	(987)
Discount to present value (1.5% to 5.0%)	<u>(1,184)</u>	<u>(1,234)</u>
Total	<u>\$ 15,489</u>	<u>32,255</u>

As of June 30, 2019 and 2018, 39% and 77% of contributions and other receivables were from one and two funding sources, respectively.

8) Deferred Revenue

The majority of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end. Deferred revenue as of June 30, 2019 and 2018 consists of the following:

	<u>2019</u>	<u>2018</u>
Special events	\$ 11,782	12,386
Service revenue	<u>1,957</u>	<u>3,857</u>
Total	<u>\$ 13,739</u>	<u>16,243</u>

9) Donated Services, Goods and Media

The value of donated goods, donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below:

	<u>2019</u>	<u>2018</u>
Donated goods	\$ 1,616	1,483
Donated services	2,924	2,950
Donated media	<u>7,447</u>	<u>3,282</u>
Total	<u>\$ 11,987</u>	<u>7,715</u>

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

10) Fixed Assets, Net

Fixed assets at June 30, 2019 and 2018 consist of the following:

	<u>2019</u>	<u>2018</u>
Leasehold improvements	\$ 2,577	2,079
Furniture, fixtures, and other office equipment	4,725	4,154
Computer equipment and software	<u>43,073</u>	<u>39,231</u>
Total	50,375	45,464
Less accumulated depreciation and amortization	<u>(41,214)</u>	<u>(36,850)</u>
Fixed assets, net	<u>\$ 9,161</u>	<u>8,614</u>

11) Retirement Plans

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee's salary and years of service. Expenses under this plan aggregated \$2,432 and \$2,336 for the years ended June 30, 2019 and 2018, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). There were no expenses incurred for the years ended June 30, 2019 and 2018. The assets of the 457 Plans are included in investments in the accompanying consolidated balance sheet and amounted to approximately \$1,747 and \$1,586 at June 30, 2019 and 2018, respectively. The liabilities of the 457 Plans are included in other long term liabilities in the accompanying consolidated balance sheet and amounted to approximately \$1,747 and \$1,586 at June 30, 2019 and 2018, respectively.

12) Lease Commitments

The leases for premises, which LLS's National Office and chapters occupy, expire on various dates through March 31, 2031, and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows:

Year ending June 30:

2020	\$ 8,522
2021	8,092
2022	7,395
2023	5,733
2024	3,364
Thereafter	<u>10,433</u>
Total	<u>\$ 43,539</u>

(continues »)

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2019
(with comparative amounts for the year ended June 30, 2018) (Amount in thousands)

13) Joint Costs Allocation

For the years ended June 30, 2019 and 2018, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows:

	<u>2019</u>	<u>2018</u>
Fundraising	\$ 10,150	7,463
Patient and community service	2,978	3,496
Public health education	<u>7,164</u>	<u>4,884</u>
Total	<u>\$ 20,292</u>	<u>15,843</u>

14) Contingent Liabilities

LLS is a defendant in various lawsuits arising in the normal course of business. Management does not expect the ultimate resolution of these actions to have a material adverse effect on LLS's financial position.

ACKNOWLEDGMENTS

Research Grants

Specialized Center of Research

The Specialized Center of Research program funds multidisciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is comprised of at least three independent research programs that are integrated and supported by scientific core laboratories.

John Cleveland, PhD, 2019
H. Lee Moffitt Cancer Center & Research Institute

Madhav Dhodapkar, MBBS, 2020*
Emory University

Dr. Madhav Dhodapkar is jointly funded by Emory University.

Helen Heslop, MD, 2019
Baylor College of Medicine

Craig Jordan, PhD, 2019
University of Colorado Denver, Anschutz Medical Campus

Dr. Craig Jordan is jointly funded by the University of Colorado Denver, Anschutz Medical Campus.

Carl June, MD, 2020*
The Trustees of the University of Pennsylvania, Medical Center

Jonathan Licht, MD, 2020*
University of Florida

Tak Mak, PhD, 2017
University Health Network

Ari Melnick, MD, 2016
Joan & Sanford I. Weill Medical College of Cornell University

Dr. Ari Melnick is funded in part by Joan & Sanford I. Weill Medical College of Cornell University and donations from the Escher Foundation, the Jim Jacobs Foundation, the LIUNA Charitable Foundation, the Melryder Foundation, and Angela and Gary Trovato.

Stephen Nimer, MD, 2018
University of Miami

Dr. Stephen Nimer is funded in part by donations from the Sylvester Comprehensive Cancer Center of the University of Miami.

Robert Orlowski, MD, PhD, 2018
The University of Texas MD Anderson Cancer Center

Andreas Strasser, PhD, FAA, MSc, 2018
Walter & Eliza Hall Institute of Medical Research

David Weinstock, MD, 2016
Dana-Farber Cancer Institute

Dr. David Weinstock is funded in part by a donation from Sandra Abbott.

Anas Younes, MD, 2017
Sloan Kettering Institute for Cancer Research

Dr. Anas Younes is funded in part by donations from the Jewish Federation of Cleveland, Sandi and Stan Kahan, and Cathy and Scott Zeilinger.

Career Development Program (Scholars and Clinical Scholars)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Omar Abdel-Wahab, MD, 2017
Sloan Kettering Institute for Cancer Research

Arash Alizadeh, MD, PhD, 2020*
Board of Trustees of the Leland Stanford Junior University

Philippe Armand, MD, PhD, 2019
Dana-Farber Cancer Institute

Saro Armenian, DO, MPH, 2017
Beckman Research Institute of the City of Hope

Uttiya Basu, PhD, 2016
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Robert Bradley, MD, 2018
Fred Hutchinson Cancer Research Center

Dr. Robert Bradley is funded in part by a donation from S Lori Brown.

Jason Butler, PhD, 2019
Hackensack Meridian Health
Fernando Camargo, PhD, 2016
Boston Children's Hospital

Grant Challen, PhD, 2019
Washington University in St. Louis

Jianjun Chen, PhD, 2018
Beckman Research Institute of the City of Hope

Jerry Chipuk, PhD, 2017
Icahn School of Medicine at Mount Sinai

Tomek Cierpicki, PhD, 2017
Regents of the University of Michigan

Simona Colla, PhD, 2019
The University of Texas MD Anderson Cancer Center

Alexey Danilov, MD, PhD, 2019
Oregon Health & Science University

Matthew Davids, MD, 2019
Dana-Farber Cancer Institute

Dr. Matthew Davids is funded in part by Dana-Farber Cancer Institute and donations from Genentech and Imagine a Cure for Leukemia.

Lei Ding, PhD, 2020*
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Todd Druley, MD, PhD, 2019**
Washington University in St. Louis

Takeshi Egawa, MD, PhD, 2018
Washington University School of Medicine in St. Louis

Areej El-Jawahri, MD, 2020*
Massachusetts General Hospital

Maria Figueroa, MD, 2019
University of Miami

Benjamin Garcia, PhD, 2016
Perelman School of Medicine at the University of Pennsylvania

Alfred Garfall, MD, 2020*
Perelman School of Medicine at the University of Pennsylvania

Ramiro Garzon, MD, 2016
The Ohio State University

Irene Ghobrial, MD, 2017
Dana-Farber Cancer Institute

Dr. Irene Ghobrial is jointly funded by Dana-Farber Cancer Institute.

David Guertin, PhD, 2016
University of Massachusetts Medical School

Alex Herrera, MD, 2019
Beckman Research Institute of the City of Hope

Dr. Alex Herrera is fully funded by a donation from Toni and Emmet Stephenson.

Katharine Hsu, MD, PhD, 2017
Sloan Kettering Institute for Cancer Research

Keisuke Ito, MD, PhD, 2019
Albert Einstein College of Medicine, Inc.

Peng Ji, MD, PhD, 2018
Northwestern University

Hao Jiang, PhD, 2019
University of Virginia

Alex Kentsis, MD, PhD, 2020*
Sloan Kettering Institute for Cancer Research

Michael Kharas, PhD, 2018
Sloan Kettering Institute for Cancer Research

Kasey Leger, MD, 2020*
Seattle Children's Hospital

Rong Lu, PhD, 2020*
University of Southern California

Dr. Rong Lu is jointly funded by the University of Southern California.

Ravindra Majeti, MD, PhD, 2016
Board of Trustees of the Leland Stanford Junior University

*Newly awarded or renewed grants in Fiscal Year 2020 **Grantee prematurely terminated award in Fiscal Year 2019

Shannon McKinney-Freeman, PhD, 2019
St. Jude Children's Research Hospital

Constantine Mitsiades, MD, PhD, 2017
Dana-Farber Cancer Institute

Alison Moskowitz, MD, 2020*
Sloan Kettering Institute for
Cancer Research

Ann Mullally, MD, 2018
Brigham and Women's Hospital

Daisuke Nakada, PhD, 2020*
Baylor College of Medicine

Lakshmi Nayak, MD, 2019
Dana-Farber Cancer Institute

Trista North, PhD, 2017
Boston Children's Hospital

Ryan O'Connell, PhD, 2018
The University of Utah

Eirini Papapetrou, MD, PhD, 2019
Icahn School of Medicine at
Mount Sinai

Christopher Park, MD, PhD, 2018
New York University School
of Medicine

Daniel Pollyea, MD, 2020*
University of Colorado Denver,
Anschutz Medical Campus

Zhijian Qian, PhD, 2019
University of Florida

Christiane Querfeld, MD, PhD, 2019
Beckman Research Institute of the
City of Hope

*Dr. Christiane Querfeld is fully
funded by a donation from the
Schwartz Ward Family Foundation.*

Kerry Rogers, MD, 2020*
The Ohio State University

Michael Savona, MD, 2019
Vanderbilt University Medical Center

Xiaobing Shi, PhD, 2017
Van Andel Research Institute

Daniel Starczynowski, PhD, 2016
Cincinnati Children's Hospital
Medical Center

Saad Usmani, MD, 2018
Atrium Health Foundation

*Dr. Saad Usmani is funded in part
by donations from Atrium Health
Foundation.*

Geoffrey Uy, MD, 2018
Washington University in St. Louis

Christopher Vakoc, MD, PhD, 2016
Cold Spring Harbor Laboratory

G. Greg Wang, PhD, 2019
The University of North Carolina at
Chapel Hill

Jian Xu, PhD, 2020*
Children's Medical Center Research
Institute at UT Southwestern

Jianhua Yu, PhD, 2019
The Ohio State University/Beckman
Research Institute of the City
of Hope

*Dr. Jianhua Yu is fully funded by a
donation from the Schwartz Ward
Family Foundation.*

Amer Zeidan, MBBS, 2019
Yale University

*Dr. Amer Zeidan is funded in part by
Yale University and a donation from
S Lori Brown.*

Career Development Program (Special Fellows and Fellows)

Robert Albero Gallego, PhD, 2020*
The Trustees of Columbia University
in the City of New York, Columbia
University Medical Center

Silvia Alvarez, PhD, 2020*
The Trustees of Columbia University
in the City of New York, Columbia
University Medical Center

Brandon Aubrey, PhD, 2019
Dana-Farber Cancer Institute

Will Bailis, PhD, 2019**
Yale University

Yael Ben-Nun, PhD, 2019
Dana-Farber Cancer Institute

Anat Biran, PhD, 2020*
Dana-Farber Cancer Institute

Juliette Bouyssou, PhD, 2020*
Dana-Farber Cancer Institute

George Burslem, PhD, 2018
Yale University

Chun-Chin Chen, PhD, 2020*
Joan & Sanford I. Weill Medical
College of Cornell University

Pan-Yu Chen, PhD, 2019
The Regents of the University of
California, San Francisco

Ryan Corces, PhD, 2018**
Board of Trustees of the Leland
Stanford Junior University

Sondra Downey-Kopyscinski, PhD,
2020*
Dana-Farber Cancer Institute

Daphné Dupéré-Richer, PhD, 2019
University of Florida

Javier Garcia Bermudez, PhD, 2020*
Rockefeller University

Mitchell Geer, PhD, 2020*
New York University School
of Medicine

Jennifer Grants, PhD, 2018
British Columbia Cancer
Agency Branch

Zhaohui Gu, PhD, 2019
St. Jude Children's Research
Hospital

Annamaria Gulla, MD, 2020*
Dana-Farber Cancer Institute

Bingqian Guo, PhD, 2018**
Harvard Medical School

Lulu Hu, PhD, 2018
The University of Chicago

Daichi Inoue, MD, PhD, 2018
Sloan Kettering Institute for Cancer
Research/Foundation for Biomedical
Research and Innovation at Kobe

Sizun Jiang, PhD, 2019
Board of Trustees of the Leland
Stanford Junior University

Gloria Jih, PhD, 2019
Regents of the University of
Michigan/The Trustees of the
University of Pennsylvania,
Medical Center

Emily Johnston, MD, 2019
The University of Alabama
at Birmingham

Courtney Jones, PhD, 2020*
University of Colorado Denver,
Anschutz Medical Campus

Niraj Joshi, PhD, 2019
Dana-Farber Cancer Institute

Vishal Khairnar, PhD, 2020*
Beckman Research Institute of the
City of Hope

Richard Jason Lamontagne, PhD,
2018
The Wistar Institute

Jianping Li, MD, 2020*
University of Florida

Shan Lin, PhD, 2020*
Dana-Farber Cancer Institute

Sydney Lu, MD, PhD, 2020*
Sloan Kettering Institute for Cancer
Research

Priya Mathur, PhD, 2018
The University of Chicago

Demis Menolfi, PhD, 2019
The Trustees of Columbia University
in the City of New York, Columbia
University Medical Center

Linde Miles, PhD, 2019
Sloan Kettering Institute for
Cancer Research

Coraline Mlynarczyk, PhD, 2019
Joan & Sanford I. Weill Medical
College of Cornell University

Lucia Morgado-Palacin, PhD, 2018
The Trustees of Columbia University
in the City of New York, Columbia
University Medical Center

Tomoya Muto, MD, PhD, 2019
Cincinnati Children's Hospital
Medical Center

Tamara Ouspenskaia, PhD, 2018
Broad Institute, Inc.

Erin Peckham-Gregory, PhD, 2020*
Baylor College of Medicine

Bibiana Rius, PhD, 2019
The Scripps Research Institute

Jacqueline Rivas, PhD, 2020*
University of Kentucky

Alejo Rodriguez Fraticelli, PhD, 2019
Boston Children's Hospital

Julia Rogers, PhD, 2020*
Harvard Medical School

Alejandro Roisman, PhD, 2020*
University of Miami

Noha Sharafeldin, MD, PhD, 2019
The University of Alabama at
Birmingham

Xiangguo Shi, PhD, 2020*
Baylor College of Medicine

Ashima Shukla, PhD, 2018
Sanford Burnham Prebys Medical
Discovery Institute

Vipul Shukla, PhD, 2018
La Jolla Institute for Allergy
and Immunology

Eric Smith, MD, PhD, 2018
Sloan Kettering Institute for
Cancer Research

*Dr. Eric Smith is funded in part
by a donation from the Names
Foundation.*

*Newly awarded or renewed grants in Fiscal Year 2020 **Grantee prematurely terminated award in Fiscal Year 2019

Alexandra Soukup, PhD, 2020*
University of Wisconsin at Madison

Pamela Sung, MD, PhD, 2020*
The Trustees of the University of
Pennsylvania, Medical Center

Brian Sworder, MD, PhD, 2019
Board of Trustees of the Leland
Stanford Junior University

Samuel Taylor, PhD, 2019
Albert Einstein College of
Medicine, Inc.

Elisa ten Hacken, PhD, 2018
Dana-Farber Cancer Institute

Rachel Thijssen, PhD, 2018
Walter & Eliza Hall Institute of
Medical Research

Daniel Utzschneider, PhD, 2019
The University of Melbourne

Leandro Venturutti, PhD, 2018
Joan & Sanford I. Weill Medical
College of Cornell University

Andrew Volk, PhD, 2020*
Northwestern University

Ly Vu, PhD, 2019
Sloan Kettering Institute for
Cancer Research

Adam Wilkinson, PhD, 2019
Board of Trustees of the Leland
Stanford Junior University

Matthew Witkowski, PhD, 2018
New York University School
of Medicine

Gongwei Wu, PhD, 2020*
Dana-Farber Cancer Institute

Min Xia, PhD, 2019
Joan & Sanford I. Weill Medical
College of Cornell University

Haopeng Yang, PhD, 2020*
The University of Texas MD
Anderson Cancer Center

William Yewdell, PhD, 2019
Sloan Kettering Institute for
Cancer Research

Christina Yim, PhD, 2020*
Sloan Kettering Institute for
Cancer Research

Akihide Yoshimi, MD, PhD, 2019
Sloan Kettering Institute for
Cancer Research

Noemi Zambetti, PhD, 2018
The Regents of the University of
California, San Francisco

Jiajun Zhu, PhD, 2018
Sloan Kettering Institute for
Cancer Research

Translational Research Program

*The Translational Research
Program supports outstanding
investigators deemed by our expert
advisors most likely to translate
basic biomedical discoveries into
new, safe and effective treatments,
ultimately prolonging and
enhancing patients' lives.*

Iannis Aifantis, PhD, 2020*
New York University School
of Medicine

Carl Allen, MD, PhD, 2018
Baylor College of Medicine

Stephen Ansell, MD, PhD, 2018
Mayo Clinic, Rochester

*Dr. Stephen Ansell is funded in
part by a donation from the
Albrecht Family.*

Scott Armstrong, MD, PhD, 2020*
Dana-Farber Cancer Institute

Fotis Asimakopoulos, MD, PhD, 2018
The Board of Regents of the
University of Wisconsin System

*Dr. Fotis Asimakopoulos is funded in
part by a donation from the Greater
Milwaukee Foundation.*

Jon Aster, MD, PhD, 2018
Brigham and Women's Hospital

Brian Baker, PhD, 2020*
University of Notre Dame

Venkata Lokesh Battula, PhD, 2020*
The University of Texas MD
Anderson Cancer Center

Smita Bhatia, MD, MPH, 2019
The University of Alabama
at Birmingham

Ranjit Bindra, MD, PhD, 2018
Yale University

Bruce Blazar, MD, 2018
University of Minnesota, Twin Cities

Patrick Brown, MD, 2020*
The Johns Hopkins University
School of Medicine

*Dr. Patrick Brown is jointly funded
by Amgen, Inc.*

Tomek Cierpicki, PhD, 2019**
Regents of the University
of Michigan

George Daley, MD, PhD, 2018
Boston Children's Hospital

Alexey Danilov, MD, PhD, 2018
Oregon Health & Science University

Hema Dave, MD, MPH, 2018
Children's Research Institute

Kara Davis, DO, 2018
Board of Trustees of the Leland
Stanford Junior University

Benjamin Ebert, MD, PhD, 2018
Dana-Farber Cancer Institute

*Dr. Benjamin Ebert is funded in
part by donations from The
Babich Family Foundation.*

Andrew Feldman, MD, 2019
Mayo Clinic, Rochester

Carolyn Felix, MD, 2019
The Children's Hospital
of Philadelphia

Adolfo Ferrando, MD, PhD, 2018
The Trustees of Columbia University
in the City of New York, Columbia
University Medical Center

David Fruman, PhD, 2020*
University of California, Irvine

Terry Fry, MD, 2020*
University of Colorado, Denver

Karin Gaensler, MD, 2018
The Regents of the University
of California, San Francisco

Jacqueline Garcia, MD, 2018
Dana-Farber Cancer Institute

Jolanta Grembecka, PhD, 2020*
Regents of the University
of Michigan

Christian Grommes, MD, 2019
Sloan Kettering Institute for
Cancer Research

Edwin Hawkins, PhD, 2018
Walter & Eliza Hall Institute of
Medical Research

Camelia Iancu-Rubin, PhD, 2019
Icahn School of Medicine at
Mount Sinai

Babal Jha, PhD, 2020*
Cleveland Clinic Foundation

Peng Ji, MD, PhD, 2020*
Northwestern University

Ricky Johnstone, PhD, 2020*
The University of Melbourne

*Dr. Ricky Johnstone is jointly funded
by Snowdome Foundation and
Leukaemia Foundation of Australia.*

Justin Kline, MD, 2020*
The University of Chicago

*Dr. Justin Kline is jointly funded by
The University of Chicago.*

Angela Koehler, PhD, 2018
Massachusetts Institute of
Technology

Robert Kridel, MD, PhD, 2020*
University Health Network

Larry Kwak, MD, PhD, 2018
Beckman Research Institute of the
City of Hope

Jatinder Lamba, PhD, 2020*
University of Florida

*Dr. Jatinder Lamba is jointly funded
by the University of Florida.*

Ronald Levy, MD, 2018
Board of Trustees of the Leland
Stanford Junior University

Timothy Ley, MD, 2018
Washington University School of
Medicine in St. Louis

Yan Liu, PhD, 2020*
Indiana University

Ivan Maillard, MD, PhD, 2020*
The Trustees of the University of
Pennsylvania, Medical Center

Ravindra Majeti, MD, PhD, 2019
Board of Trustees of the Leland
Stanford Junior University

Sami Malek, MD, 2020*
Regents of the University
of Michigan

Maksim Mamonkin, PhD, 2019
Baylor College of Medicine

Ari Melnick, MD, 2019
Joan & Sanford I. Weill Medical
College of Cornell University

Soheil Meshinchi, MD, PhD, 2020*
Fred Hutchinson Cancer
Research Center

Constantine Mitsiades, MD, PhD,
2018
Dana-Farber Cancer Institute

Gareth Morgan, MD, PhD, FRCP,
FRCPATH, 2020*
New York University School
of Medicine

*Newly awarded or renewed grants in Fiscal Year 2020 **Grantee prematurely terminated award in Fiscal Year 2019

Charles Mullighan, MD, 2020*
St. Jude Children's Research
Hospital

*Dr. Charles Mullighan is jointly
funded by Snowdome Foundation
and Leukaemia Foundation
of Australia.*

Ryotaro Nakamura, MD, 2020*
Beckman Research Institute of the
City of Hope

*Dr. Ryotaro Nakamura is jointly
funded by Beckman Research
Institute of the City of Hope.*

Sattva Neelapu, MD, 2020*
The University of Texas MD
Anderson Cancer Center

Stephen Nimer, MD, 2018
University of Miami

*Dr. Stephen Nimer is funded in
part by donations from The Babich
Family Foundation.*

Stephen Nutt, PhD, 2020*
Walter & Eliza Hall Institute of
Medical Research

*Dr. Stephen Nutt is jointly funded
by Snowdome Foundation and
Leukaemia Foundation of Australia.*

Owen O'Connor, MD, PhD, 2020*
The Trustees of Columbia University
in the City of New York, Columbia
University Medical Center

*Dr. Owen O'Connor is jointly funded
by The Trustees of Columbia
University in the City of New York,
Columbia University Medical Center.*

Jae Park, MD, 2018
Sloan Kettering Institute for
Cancer Research

*Dr. Jae Park is funded in part by
donations from Edith Klein, the
Hairy Cell Leukemia Foundation,
and The SASS Foundation for
Medical Research, Inc.*

Laura Pasqualucci, MD, 2019
The Trustees of Columbia
University in the City of New York
- Morningside

Joel Pomerantz, PhD, 2020*
The Johns Hopkins University
School of Medicine

Sean Post, PhD, 2019
The University of Texas MD
Anderson Cancer Center

Jun Qi, PhD, 2018
Dana-Farber Cancer Institute

Katy Rezvani, MD, PhD, 2018
The University of Texas MD
Anderson Cancer Center

Rizwan Romee, MD, 2020*
Dana-Farber Cancer Institute

Steven Rosen, MD, 2019
Beckman Research Institute of the
City of Hope

Davide Rossi, MD, PhD, 2020*
Foundation for the Institute of
Oncology Research

Michael Rout, PhD, 2020*
Rockefeller University

Kathleen Sakamoto, MD, PhD, 2020*
Board of Trustees of the Leland
Stanford Junior University

Deepa Sampath, MD, PhD, 2018
The Ohio State University

Guy Sauvageau, MD, PhD, FRCPC,
2018
Institute for Research in Immunology
and Cancer

*Dr. Guy Sauvageau is funded in
part by donations from The Babich
Family Foundation.*

Barbara Savoldo, MD, PhD, 2018
The University of North Carolina at
Chapel Hill

Mala Shanmugam, PhD, 2019
Emory University

Kevin Shannon, MD, 2020*
The Regents of the University of
California, San Francisco

*Dr. Kevin Shannon is jointly funded
by The Regents of the University of
California, San Francisco.*

Aditi Shastri, MD, 2020*
Montefiore Medical Center

Margaret Shipp, MD, 2020*
Dana-Farber Cancer Institute

Lev Silberstein, MD, PhD, 2018
Fred Hutchinson Cancer
Research Center

Tomasz Skorski, MD, PhD, DSc, 2019
Temple University

Karin Tarte, PhD, 2020*
National Institute of Health and
Medical Research

Enrico Tiacchi, MD, 2018
University of Perugia

*Dr. Enrico Tiacchi is funded in part by
donations from Edith Klein, the Hairy
Cell Leukemia Foundation, and
The SASS Foundation for Medical
Research, Inc.*

Wei Tong, PhD, 2018
The Children's Hospital of
Philadelphia

Ashwin Unnikrishnan, PhD, 2020*
The University of New South Wales

*Dr. Ashwin Unnikrishnan is jointly
funded by Snowdome Foundation
and Leukaemia Foundation
of Australia.*

Amit Verma, MD, 2019
Albert Einstein College of
Medicine, Inc.

Dan Vogl, MD, 2020*
The Trustees of the University of
Pennsylvania, Medical Center

Loren Walensky, MD, PhD, 2020*
Dana-Farber Cancer Institute

*Dr. Loren Walensky is funded in
part by a donation from Lisa and
James LaTorre.*

Brian Walker, PhD, 2020*
University of Arkansas for Medical
Sciences

Kirsten Williams, MD, 2019
Children's Research Institute

*Dr. Kirsten Williams is funded in part
by a donation from The Holland C.
Gregg IV Research Fund.*

Kai Wucherpfennig, MD, PhD, 2019
Dana-Farber Cancer Institute

Andrew Zannettino, PhD, 2018
The University of Adelaide

Fenghuang Zhan, MD, PhD, 2018
The University of Iowa

Baochun Zhang, MD, PhD, 2020*
Dana-Farber Cancer Institute

Translational Research Program: Renewal

Katherine Borden, PhD, 2020*
Institute for Research in Immunology
and Cancer

Leandro Cerchietti, MD, 2019
Joan & Sanford I. Weill Medical
College of Cornell University

*Dr. Leandro Cerchietti is funded in
part by a donation from Jane Elissa/
Charlotte Meyers Endowment Fund.*

Mignon Loh, MD, 2019
The Regents of the University of
California, San Francisco

Feyruz Rassool, PhD, 2019
University of Maryland at Baltimore

Aaron Schimmer, MD, PhD, 2020*
Princess Margaret Cancer Center,
University Health Network

Screen to Lead Program

*The Screen to Lead Program offers
drug discovery support specifically
directed towards medicinal chemistry
and/or drug target screening in
hematological malignancies.*

Jolanta Grembecka, PhD, 2020*
Regents of the University
of Michigan

John Sondek, PhD, 2020*
The University of North Carolina
at Chapel Hill

New Idea Award

*The New Idea Award is a concept
award that funds innovative
approaches that may fundamentally
change the understanding,
diagnosis and/or treatment of blood
cancers and related premalignant
conditions.*

Mark Cobbold, MD, PhD, 2019
Massachusetts General Hospital

MPN Challenge Grants

*This program is run in partnership
with the MPN Research Foundation.*

Matyas Ecsedi, MD, PhD, 2020*
Fred Hutchinson Cancer Research
Center

Yelena Ginzburg, MD, 2020*
Icahn School of Medicine at
Mount Sinai

Vikas Gupta, MD, 2020*
Princess Margaret Cancer Center,
University Health Network

Catriona Jamieson, MD, PhD, 2020*
The Regents of the University of
California, San Diego

Alison Moliterno, MD, 2020*
The Johns Hopkins University
School of Medicine

Jyoti Nangalia, PhD, 2020*
Wellcome Trust Sanger Institute

Vijay Sankaran, MD, PhD, 2020*
Boston Children's Hospital

*Newly awarded or renewed grants in Fiscal Year 2020 **Grantee prematurely terminated award in Fiscal Year 2019

IWMF Grants

This program is run in partnership with the International Waldenstrom's Macroglobulinemia Foundation.

Yong Li, PhD, 2020*
Cleveland Clinic Foundation

Constantine Mitsiades, MD, PhD, 2020*
Dana-Farber Cancer Institute

Marcel Spaargaren, PhD, 2020*
Academic Medical Center
Amsterdam

Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Prevention Grants for Blood Cancer

This program is run in partnership to advance breakthroughs in the prevention of blood cancers.

C. Ola Landgren, MD, PhD, 2019
Sloan Kettering Institute for Cancer Research

Dr. C. Ola Landgren is funded in part by a donation from Wrobel Family Foundation.

Liran Shlush, MD, PhD, 2019
Weizmann Institute of Science

Dr. Liran Shlush is funded in part by a donation from Wrobel Family Foundation.

George Vassiliou, MD, PhD 2019
Wellcome Trust Sanger Institute

Dr. George Vassiliou is funded in part by a donation from Wrobel Family Foundation.

Mantle Cell Lymphoma Research Initiative

The Mantle Cell Lymphoma Research Initiative supports teams of researchers representing different disciplines and engaging in collaborative efforts to discover new approaches to treat patients with blood cancers.

Selina Chen-Kiang, PhD, 2019
Joan & Sanford I. Weill Medical College of Cornell University

Dr. Selina Chen-Kiang is funded in part by donations from Steven M. Durham and The Sarah Cannon Fund at the HCA Foundation.

Larry Kwak, MD, PhD 2019
Beckman Research Institute of the City of Hope

Dr. Larry Kwak is funded in part by donations from Steven M. Durham and The Sarah Cannon Fund at the HCA Foundation.

PedAL

LLS PedAL is a global precision medicine master clinical trial that will test multiple targeted therapies for relapsed acute leukemia simultaneously at up to 200 clinical sites worldwide. We are setting the groundwork for LLS PedAL throughout 2019, with the goal of treating the first patient in the summer of 2020.

Todd Cooper, DO, 2020*
Seattle Children's Hospital

E. Anders Kolb, MD, 2020*
Nemours Alfred I. duPont Hospital for Children

Samuel Volchenbom, MD, PhD, 2020*
The University of Chicago

Special Initiatives

Peter Adamson, MD, 2019
The Children's Hospital of Philadelphia

Dr. Peter Adamson is funded in part by a donation from Bayer Healthcare Pharmaceuticals.

Carma Bylund, PhD, 2020*
University of Florida

Dr. Carma Bylund is funded in part by a donation from the Carolan Research Institute.

Rena Conti, PhD, 2019
The University of Chicago

Amy Davidoff, PhD, 2020*
Yale University School of Medicine

Stacie Dusetzina, PhD, 2020*
Vanderbilt University Medical Center

Oliver Jonas, PhD, 2020*
Brigham and Women's Hospital

Dr. Oliver Jonas is funded in part by a donation from Dr. Ralph & Marian Falk Medical Research Trust.

E. Anders Kolb, MD, 2019
Nemours Alfred I. duPont Hospital for Children

Dr. E. Anders Kolb is funded in part by a donation from Bayer Healthcare Pharmaceuticals.

Soheil Meshinchi, MD, PhD, 2019
Fred Hutchinson Cancer Research Center

Dr. Soheil Meshinchi is funded in part by a donation from Bayer Healthcare Pharmaceuticals.

Markus Muschen, MD, PhD, 2020*
Beckman Research Institute of the City of Hope

Dr. Markus Muschen is funded in part by a donation from Dr. Ralph & Marian Falk Medical Research Trust.

Susan Parsons, MD, 2020*
Tufts Medical Center

David Teachey, MD, 2019
The Children's Hospital of Philadelphia

Dr. David Teachey is jointly funded by The Children's Hospital of Philadelphia.

*Newly awarded or renewed grants in Fiscal Year 2020 **Grantee prematurely terminated award in Fiscal Year 2019

Partnerships

Therapy Acceleration Program Partnerships

Biotechnology Partners

Acetylon Pharmaceuticals, Inc.
Boston, MA

Affimed Therapeutics AG
Heidelberg, Germany

Constellation Pharmaceuticals, Inc.
Cambridge, MA

Decoy Biosciences, Inc.
San Diego, CA

Forty Seven, Inc.
Menlo Park, CA

ImmunGene, Inc.
Camarillo, CA

KDAC Therapeutics, Inc.
Cambridge, MA

Kiadis Pharma NV
Amsterdam, Netherlands

miRagen Therapeutics, Inc.*
Boulder, CO

NexImmune, Inc.
Gaithersburg, MD

OncoPep, Inc.
North Andover, MA

Ryvu Therapeutics SA
Krakow, Poland

Stemline Therapeutics, Inc.
New York, NY

Sutro Biopharma, Inc.
San Francisco, CA

Travera, LLC
Cambridge, MA

Verastem Oncology
Needham, MA

X4 Pharmaceuticals, Inc.**
Cambridge, MA

**Equity investment of \$1,000,000
in Fiscal Year 2019*

***Equity investment of \$3,300,000
in Fiscal Year 2019*

Academic Partners

Case Western Reserve University
Cleveland, OH

Herbert Irving Comprehensive
Cancer Center at Columbia
University Medical Center
New York, NY

The Sidney Kimmel
Comprehensive Cancer Center
at Johns Hopkins University
Baltimore, MD

The University of Texas
MD Anderson Cancer Center
Houston, TX

Oregon Health & Science University
Portland, OR

Advisors

Medical & Scientific Affairs Committee

Steven Rosen, MD, FACP
Beckman Research Institute of
the City of Hope
Chair

Stephen Ansell, MD, PhD
Mayo Clinic, Rochester

P. Leif Bergsagel, MD
Mayo Clinic, Arizona

Ravi Bhatia, MD
The University of Alabama at
Birmingham

Catherine Bollard, MD, MBChB
Children's Research Institute

S. Lori Brown, PhD, MPH
Former U.S. Food & Drug
Administration

Renzo Canetta, MD
Former Bristol-Myers Squibb

Giulio Draetta, MD, PhD
The University of Texas
MD Anderson Cancer Center

Christopher Flowers, MD
The University of Texas
MD Anderson Cancer Center

Janice Gabrilove, MD
Icahn School of Medicine at
Mount Sinai

Irene Ghobrial, MD
Dana-Farber Cancer Institute

Larry Kwak, MD, PhD
Beckman Research Institute of
the City of Hope

Michelle LeBeau, PhD
The University of Chicago

Ross Levine, MD
Sloan Kettering Institute for
Cancer Research

Jonathan D. Licht, MD
University of Florida

Ruben Mesa, MD
The University of Texas Health
Science Center at San Antonio

Susan M. O'Brien, MD
The Regents of the University
of California, Irvine

David Weinstock, MD
Dana-Farber Cancer Institute

Therapy Acceleration Program Committee

Co-Chairs

Dana Callow, MBA
Boston Millennia Partners

C. Casey Cunningham, MD
Santé Ventures

Members

William S. Dalton, MD, PhD¹
M2Gen

Giulio Draetta, MD, PhD
The University of Texas
MD Anderson Cancer Center

Christopher Flowers, MD
The University of Texas
MD Anderson Cancer Center

Laura S. Kaufman, PhD, DABT
Private Consultant

Ross L. Levine, MD¹
Sloan Kettering Institute for
Cancer Research

Ronald Levy, MD
The Board of Trustees of the Leland
Stanford Junior University

Vern Norviel, JD
Wilson Sonsini Goodrich & Rosati

Susan M. O'Brien, MD
The Regents of the University
of California, Irvine

Robert J. Rosen, JD
Greyhawke Capital Advisors

Steven T. Rosen, MD, FACP
Beckman Research Institute of
the City of Hope

David Weinstock, MD²
Dana-Farber Cancer Institute

¹ ended service in January 2019
² started service in January 2019

2019 National Recognition & Awards Program

We are pleased to recognize the extraordinary involvement of individuals, companies, corporations and organizations in their support of LLS and its mission. Those honored give of their time, talent and treasury and have made a significant difference in the lives of so many. To find out more about our awards program, please go to <http://www.LLS.org/national-awards-nomination>.

Congratulations to all the 2019 awardees!

National Recognition & Awards Recipients

President's Award

This award recognizes a volunteer whose personal commitment and dedication inspires and motivates others to support our mission.

Charles Esten & Family
Tennessee Chapter

Robert de Villiers Spiral of Life Award

This award honors the memory of Robert de Villiers whose parents Rudolph and Antoinette de Villiers founded a foundation that is now known as The Leukemia & Lymphoma Society.

The award recognizes an individual who through their leadership and tireless effort to raise funds and influence policy has advanced the mission of LLS.

Tom Philbrick, MD
Georgia Chapter

Robert (Bob) Dean
Greater Sacramento Area Chapter

Dr. Jerry Adams
Australia

Vision for Life Award

This award recognizes an individual, corporation or organization whose ability to think outside of the box has helped to create a new fundraising campaign/program or has enhanced an existing event that has national potential.

Amanda Tiede
National Capital Area Chapter

Colton's Army
Washington/Alaska Chapter

Advocacy Award

This award recognizes the commitment and dedication of individuals who support the Office of Public Policy initiatives.

William Teator
Upstate New York/Vermont Chapter

Leadership Award

This award recognizes an individual who has been active in a chapter for at least three years and has provided expertise and guidance that have helped the chapter achieve new levels of success.

Gregg & Karen Ritchie
California Southland Chapter

Scott Jackson
Eastern Pennsylvania Chapter

Bill Rawlings
Georgia Chapter

K.Sue Duncan
Greater Bay Area Chapter

Roland Guillen
Greater Sacramento Area Chapter

Carmen Cruz
Long Island Chapter

Robert and Jenny Kotler
Mississippi/Louisiana Chapter

Tom Davis
North Carolina Chapter

Miller Paint
Oregon SW Washington Idaho
Montana Chapter

Ronda Conger
Oregon SW Washington Idaho
Montana Chapter

Sam Forrest
Palm Beach/Treasure Coast Chapter

Bryan Austin
Rocky Mountain Chapter

Enerplus Resources (USA)
Corporation
Rocky Mountain Chapter

Heath Melton
Texas Gulf Coast Chapter

Jim Carman
Texas Gulf Coast Chapter

Marshall Esler
Tri-State Southern Ohio Chapter

Eric Davis
Tri-State Southern Ohio Chapter

AJ Bodden
Upstate New York/Vermont Chapter

Bill Torney
Virginia Chapter

Jason Mascitti
Wisconsin Chapter

Quality of Life Award

This award recognizes a member of the medical community, a social worker, or a caregiver, who has provided outstanding support, counsel or guidance to blood cancer patients or their families.

John M. Timmerman, MD
California Southland Chapter

Neal Rosen
Greater Bay Area Chapter

Dulcy Wilson
Greater Sacramento Area Chapter

Jamie McDonald, LCSW
New Mexico Chapter

Kathryn Kolibaba, MD
Compass Oncology

Oregon SW Washington Idaho
Montana Chapter

Jack Aiello
Silicon Valley & Monterey Bay
Area Chapter

Larry Nielsen
Upstate New York/Vermont Chapter

Dr. Scott Kruger
Virginia Chapter

Dr. Richard Hansen
Wisconsin Chapter

Special Recognition Award

This award recognizes an individual who is deserving of recognition for their outstanding commitment to an event or program that has resulted in increasing revenue and building public awareness of LLS.

TGI Fridays - The Briad Group
California Southland Chapter

Gregg Metcalf
Georgia Chapter

Caitlin Grace
Greater Bay Area Chapter

Arlette Garcia
Greater Sacramento Area Chapter

David Mutnick
Illinois Chapter

Brenda McCarthy
Long Island Chapter

Marc and Shari Weissbach
Long Island Chapter

Jennifer Oz
Orange County Inland
Empire Chapter

I Choose Joy
Oregon SW Washington Idaho
Montana Chapter

Katlin Cauffman
Oregon SW Washington Idaho
Montana Chapter

Paige McCoy
Rocky Mountain Chapter

Ron Cohn
San Diego Chapter

Dr. Grenita Lathan
Texas Gulf Coast Chapter

Elizabeth Jordan
Texas Gulf Coast Chapter

Howard Hughes Corporation
Texas Gulf Coast Chapter

Dave Bookman
Tri-State Southern Ohio Chapter

Tom and Sheila Kwest
Tri-State Southern Ohio Chapter

Diane Simon
Virginia Chapter

Erin McFarland
Virginia Chapter

Nancy Boman
Washington/Alaska Chapter

Sandy Hickey
Washington/Alaska Chapter

Partners Against Blood Cancer Award

The Partners Against Blood Cancer Award recognizes an individual, corporation or organization that has demonstrated their ongoing support and enduring commitment to LLS.

Diamond 30+ years of participation

Columbia Center
Washington/Alaska Chapter

Platinum 20+ years of participation

Astex Pharmaceuticals, Inc.
Greater Bay Area Chapter

The Niello Company
Greater Sacramento Area Chapter

Gold 15+ years of participation

SoCalGas - A Sempra
Energy Utility
California Southland Chapter

Hy-Vee, Inc.
Iowa Chapter

The Party Source
Tri-State Southern Ohio Chapter

Silver 10+ years of participation

Manatt
California Southland Chapter

St. Francis School
Georgia Chapter

Woodward Academy
Georgia Chapter

MARSH
Greater Bay Area Chapter

Bender Insurance Solutions
Greater Sacramento Area Chapter

Rampart High School
Rocky Mountain Chapter

Furniture Fair
Tri-State Southern Ohio Chapter

Oncology Hematology Care, Inc.
Tri-State Southern Ohio Chapter

Seattle Genetics
Washington/Alaska Chapter

Team Survivor – Reuben Canales
Wisconsin Chapter

Team Survivor – The DeGroot
Family
Wisconsin Chapter

The Marcus Corporation
Wisconsin Chapter

Bronze 5+ years of participation

Gregory James
Greater Sacramento Area Chapter

KPMG
Illinois Chapter

Special Recognition Citations

These citations recognize retail establishments who have partnered with their customers to support LLS.

TGI Fridays - The Briad Group
California Southland Chapter

Jimboy's Tacos
Greater Sacramento Area Chapter

Dan's Supreme Key Foods
Long Island Chapter

Jersey Mike's
Minnesota, North Dakota, South
Dakota Chapter

Team Nike
Oregon SW Washington Idaho
Montana Chapter

Sam's No. 3
Rocky Mountain Chapter

Yogurtland
Rocky Mountain Chapter

TrueNorth Shell
Tri-State Southern Ohio Chapter

Jersey Mike's
Wisconsin Chapter

Media Awards Recipients

Recipients have a record of excellence in fundraising and promotional support, as well as educating and informing the public of LLS and its mission.

Digital Media

Clear Channel Outdoor
Minnesota Chapter

Brew Creative Media
Minnesota Chapter

Print Journalism

Comstock's Magazine
Greater Sacramento Area Chapter

The Modesto Bee
Greater Sacramento Area Chapter

Cancer Wellness Magazine
Illinois Chapter

Chris Ohmer
Cincinnati Magazine
Tri-State Southern Ohio Chapter

Cincinnati Magazine
Tri-State Southern Ohio Chapter

Radio

Nick McIlwain
Preston & Steve Show
Eastern Pennsylvania Chapter

WMMR 93.3
Preston & Steve Show
Eastern Pennsylvania Chapter

Hubbard Radio
Gateway Chapter

Cumulus Radio Station
Group I Minneapolis
Minnesota Chapter

Hubbard Radio
WIRK, WRMF
Palm Beach/Treasure Coast Chapter

Melanie Rutledge
KOOL 105
Rocky Mountain Chapter

KOOL 105
Rocky Mountain Chapter

104.5 The Zone
Tennessee Chapter

Sunny 99.1
Texas Gulf Coast Chapter

iHeartMedia - Seattle
Washington/Alaska Chapter

Television

KMOV St. Louis
Gateway Chapter

Toni Valliere
KCRA 3
Greater Sacramento
Area Chapter

KCRA 3
Greater Sacramento
Area Chapter

Good Day Sacramento
KMAX
Greater Sacramento
Area Chapter

WGN-TV
Illinois Chapter

FOX 9 KMSP
Minnesota Chapter

KFYR-TV
Minnesota Chapter

Clay Loney
FOX 23-TV
Tulsa, OK
Oklahoma Chapter

FOX 23-TV
Tulsa, OK
Oklahoma Chapter

Ernie Zuniga
KABB Fox 29
South-Central Texas Chapter

KABB Fox 29
South-Central Texas Chapter

Special Recognition

John Occhipinti
Oklahoma Chapter

Dr. William Dameshek Award

This award honors the memory of Dr. William Dameshek who was a pioneer in developing chemotherapy protocols and who founded the core hematology journal Blood and served as its editor for many, many years.

This award recognizes nationally recognized notables and celebrities who have lent their voice and image to advance the LLS mission.

The Beach Boys
Oklahoma Chapter

John Stamos
Oklahoma Chapter

Dana Tyson
Texas Gulf Coast Chapter

Donors

We gratefully acknowledge the individuals, foundations and corporations that generously supported LLS's mission during this fiscal year.

Pharmaceutical Funding Legend

- Ⓟ Patient Access
- Ⓟ Public Policy
- Ⓡ Research
- Ⓢ Campaign

* Denotes multi-year commitment

President's Circle \$1,000,000 and Above

Monica and Timothy Babich*
 Jeff Binder
 Burlington
 Celgene Corporation Ⓟ Ⓢ
 Cynthia and Frank Gasztonyi*
 Dr. Ralph & Marian Falk Medical Research Trust*
 Genentech/Biogen Ⓟ Ⓢ Ⓡ Ⓟ
 Gilead Sciences, Inc. Ⓟ
 The Harry T. Mangurian Jr. Foundation, Inc.*
 Jazz Pharmaceuticals, Inc. Ⓟ Ⓢ
 LIUNA Charitable Foundation*
 The Lyon Family Foundation*
 Pharmacyclics/Janssen Ⓟ Ⓢ Ⓟ
 Donald Porteous*
 Joan and Paul Rubschlagher*
 The Sarah Cannon Fund at the HCA Foundation*
 Schwartz Ward Foundation*
 Subaru of America Inc.
 Takeda Oncology Ⓟ
 UFCW
 Walgreens
 The Wawa Foundation
 Anonymous (1 donor)

Leadership Circle \$500,000-\$999,999

AbbVie Inc. Ⓟ Ⓢ
 Amgen Inc. Ⓟ Ⓢ
 Astellas Pharma US, Inc. Ⓟ Ⓢ
 Bloomberg Philanthropies
 Carolan Research Institute*
 Don & Lorraine Freeberg Foundation
 Kite, A Gilead Company Ⓟ Ⓢ
 Lang / Stiglitz Family Fund
 Katherine and James Lau*
 Leukaemia Foundation*
 MUY Hamburger Partners LLC
 The Norcross Foundation, Inc. In Memory of Herrick F. Norcross, Jr. (Rick)*
 Novartis Pharmaceuticals Ⓟ
 Lynne and Greg O'Brien*
 Salesforce
 Snowdome Foundation*
 Toni and Emmet Stephenson*

Innovation Circle \$250,000-\$499,999

AstraZeneca Pharmaceuticals Ⓟ Ⓢ Ⓡ
 Atrium Health Foundation*
 Bayer Ⓢ
 Bristol-Myers Squibb Ⓟ
 The Charles T. Bauer Charitable Foundation*
 Charles Esten*
 Global Franchise Group, LLC - Great American Cookies®, Hot Dog on a Stick®, Marble Slab Creamery®, Maggie Moo's Ice Cream & Treatery®, Pretzelmaker®, and Round Table Pizza®
 Green Tie Gala/Chuck Cuda
 GSP Transportation, Inc.
 Jersey Mike's Subs
 Kenneth & Verna Mae Jessen Trust
 The Orokawa Foundation, Inc.
 Pfizer, Inc. Ⓟ
 Shoot For A Cure
 Stater Bros. Markets

Mona Carlton Stogner and Grey Stogner*
 Anonymous (1 donor)

\$100,000-\$249,000

Albert & Elaine Borchard Foundation
 The Alice Lawrence Foundation
 Alto-Shaam, Inc.
 Anna and Dean Backer*
 John and Nonnie Barbey
 BD
 Black Dog Charity
 Bloomberg
 William and Tamea Bock
 The Boldt Family Philanthropy Fund*
 BR Purchasing
 Janice and Peter Brock*
 S. Lori Brown
 Cal Turner Family Foundation*
 Celebrity Cruises
 The Charles Engelhard Foundation*
 Lisa Norcia Cheskin and Barry Cheskin*
 The Chicago Community Foundation
 Cleveland Clinic
 Michael and Liz Copley*
 Custom Ink
 Daiichi Sankyo Ⓟ
 Robert and Cindy Dickinson
 John and Ann Doerr
 Earl D. and Marian N. Olson Fund
 The Edward J. Phillips Family Foundation*
 Enmark Stations, Inc.
 F. M. Kirby Foundation, Inc.
 Chiyoko Furukawa*
 Greater Milwaukee Foundation, Inc.*
 The Hairy Cell Leukemia Foundation*
 The Hearst Foundation
 Higgins Family Charitable Foundation
 Incyte Corporation Ⓟ
 The J.T. Tai & Co. Foundation, Inc.
 William and Jennifer Kenneally*
 The Laborers Charitable Foundation

Joyce and Larry Lacerte*
 Paul Leinwand
 Jeannie and Steve Lieblich*
 Cristine and Timothy Lindenfelser
 Mable Hamann Revocable Trust
 Clyde McGregor and LeeAnn Pederson Pope
 Melisa Reasner McGuire Advised Endowment Fund
 Memorial Cancer Institute
 Melovee White Trust Alice L Clare Trustee
 Nike, Inc.
 NSC Global
 Rick Ostroff*
 Pennsylvania Department of Health
 Presidio
 PSEG Foundation
 PWC
 Rahr Corporation*
 Pat and Jeff Sachs*
 The SASS Foundation for Medical Research, Inc.*
 Jeff Schoepfel
 Michael Scotece
 Silicon Valley Bank
 Stanford Children's Health
 Stifel
 Sylvester Comprehensive Cancer Center, University of Miami
 Teva Pharmaceuticals Ⓟ
 Gary and Angela Trovato*
 TrueNorth Energy
 UCLA Health
 VyStar Credit Union
 West Marine
 Wrobel Family Foundation
 Roger Zacher
 Anonymous (4 donors)

Discovery Circle \$50,000-\$99,999

27th Investments LLC
ADP
Agius Pharmaceuticals, Inc. (PA)
Akin Gump Strauss Hauer & Feld, LLP
Allegheny Foundation
ArcherDX
Avella Specialty Pharmacy (C)
The Batchelor Foundation, Inc.
BDO USA LLP
Blue Lagoon Foundation
BlueCross BlueShield of Alabama
Bob Moore Subaru
Boscov's Home Office
CareFirst BlueCross BlueShield
Vanessa and Mark Cereceda
The Chelsea Morrison Foundation
Compass Self-Storage, LLC
Dan and JoAnne Coolidge*
D.M. Foundation
DC'S Dancing Stars Gala
Deseret Trust Company
Don Mealey Subaru Sport
Ecolab
Elbit System of America
Elevation Church
Entergy Texas
Gary and Susan Farmer
John Fitch
FIS
Flamingo Inc.
Florida Cancer Specialists
Freeman Expositions, LLC
Garden City Turkey Trot
The Gaughen Management Group
Geico
Generac Power Systems, Inc.
Georgia Power Company
Hannig Law
Harold Salmanowitz Charitable
Lead Trust
Dan Harrington
The Hatton Foundation
Marianne Heatherly
Heritage Title
Hildegard D. Becher
Foundation Inc.
HM Insurance Group
Howard Family Foundation
John and Kristin Hyland
IBERIABANK
Ice Mobility Foundation

Imagine a Cure for Leukemia
Iron Bow Technologies
Jackson Family Fund
JAE Restaurant Group
Janssen Biotech (PA) (R)
The Jerry C. Dearing Family
Foundation
JLL
The John and Frances Beck
Family Foundation
Johnson & Johnson
Joseph Kelley
Keystone Holdings
Kindred Healthcare Operating, Inc.
Kingsbury Family Fund
Koppers, Inc.
KPMG
Krispy Krunchy Foods, LLC
L & R Structural Corp.
Lanphere Auto Group
Lehigh Valley Restaurant Group, Inc.
/Red Robin
Lighthouse Partner
Judy and Charlie Lynch*
Maine Cancer Foundation
Joe Maio
McKesson Specialty Health
Medical Properties Trust
Corrine and Jon Merksamer*
Miami Cancer Institute
Mikuni Charitable Organization
Montgall Scholarship Fund, Inc.
The Moorings
Nancy Nasher and David
Haimesseger
The Nashville Wine Auction
Chris Neibauer
Nimick Forbesway Foundation
Norwegian Cruise Line
Lindsey Noto
Opal Wealth Advisors
Ostroff Associates
Kaylene and Rajiv Patel
Pieper Electric, Inc.
The Ping Y. Tai Foundation, Inc.
PinkTie.org
Pizza Hut of America, Inc.
Planned Systems International
PNC Bank
Fred and Cherie Pond*
PRA Health Sciences
Dr. George Rapier
Barbara and Brent Reid
Robert E. Gallagher Charitable Trust

Melody and Rick Rogers
Lois and Jerry Rosenblum
Sagepoint Financial, Inc.
Stacy Sager
SagerStrong Foundation Inc.
SAIC
Salt River Pima-Maricopa Indian
Community (SRPMIC)
Neil Salvage
Sarver Charitable Trust
Seattle Genetics (PA)
Sempra Energy
Mr. and Mrs. Richard Smith
Snap Crack Chiropractic
Margaret and Donald Steiner
SummitG
Survivor Spotlight
Mark Taylor
Thrivent Choice Wisconsin
United Way of San Antonio and
Bexar County
Verizon
VGM Associates Ltd.
The Victor E. & Caroline E.
Schutte Foundation
The Walt Disney Company
The Ward Law Group
Wells Fargo
Wendmiddle LLC
West Pharmaceutical
Services, Inc. (C)
Wilhelm Restaurant Group, Inc.
Anonymous (2 donors)

\$25,000-\$49,999

1889 Foundation
7 Eleven, Inc.
Jim Abedi
ABM Industries
Kenneth Aboussie
Advent Health
The Alice Lawrence Foundation, Inc.
Alston Construction
Alverin M. Cornell Foundation
AM Charity Fund
Ameren Missouri
ANF Group
Michael Arougheti
Arthur M. Blank Family Foundation
Assemi Group, Inc.
Assurance Power Systems
Astex Pharmaceuticals, Inc. (C)
AT&T
The Aurora Highlands

AutoNation Subaru Hunt Valley
Bank of America
Joseph Baratta
Barclays Bank Delaware
Barings
Traci and Tedd Barr
Baylor Scott & White
BeiGene, Ltd
Belk
Berkshire Bank
Biologics By McKesson
Bireley Family Foundation
Blackbaud
Andrew and Danielle Blass
BlueCross BlueShield of
South Carolina
Ed and Susan Blumenfeld
Bobby & Steve's Auto World
Youth Foundation
Bon Secours St Francis
Brayton Purcell, LLP
Briggs Equipment
JD Brooks
Jeff and Becky Burch
The C. Kenneth & Laura Baxter
Foundation
Jack Callon
Camelback Subaru
Cancer Treatment Centers of
America Global Inc.
Carlos Batista Foundation
Carlson Family Foundation, Inc.
Charles and Chris Carroll
Carz Cruizn Inc.
CBRE Group
Cedar Fair Charities
Centene Corporation
Certainty Home Loans
Kalpana Chakraburty
Charles McMurray Co.
Chemed Foundation
Chicago Title
Chickasaw Nation
Children's Mercy Hospital
Circle City Foundation
Citi Business Services
Citrix
CityWorth
CNA
Ron and Guadalupe Cohn
Communities Foundation of Texas
Community Foundation
Sonoma County*
Community Health Network

Cool Springs Financial	GDIT	Luck Stone Corporation	Perfumania
Cora and John H. Davis Foundation	General Dynamics	Lunardi's Markets	Sonja and Jon Perkins
Costco Charitable	Genesee Mountain Foundation	The Luppe and Paula Luppen Family Foundation	Tracy Peters
Kevin Coxon	Giant Food	Luther White Bear Subaru	Scott Peyree
Cruise Planners	Global Atlantic Financial Group	M&T Bank	PFG/Vistar
Dana Farber Cancer Institute	Grant Thornton LLP	M&T Bank/Wilmington Trust	Drs. Bud and Selma Pierce
The Danaher Foundation	H. Lee Moffitt Cancer Center & Research Institute	M.G. O'Neil Foundation	Pray Family Foundation
Dayton Children's Hospital	HAC, Inc.	Marcus and Millichap	Protiviti
Dealer Tire	Nancy Hamlin	The Marcus Foundation, Inc.	Prudential Financial
Michael Del Giudice	Hargrove Foundation	Lois Markovich	PurePoint Financial
Delaware Community Blood Foundation, Inc.	John Harrison	Paula and Larry Marshall	Rambus
Desert States Charitable Foundation	Healthcare Management Administrators	Mason City School District	Rathgeber Investment GP Inc.
Dickinson Fleet Services LLC	HealthEquity	Massapequa Turkey Trot	RCCA
Dan Diepenhorst	Heartland Blood Centers	Mr. and Mrs. Bryan Mattson	Lisa and Robert Reeves
Digital Federal Credit Union	HEB	MAXIMUS	REMAX Gateway
Dignity Health	Alice Hejl	Mays Family Foundation	Rheingold Family
Dominion Energy	Kathleen and Mark Helge	McCaffery Interests Inc.	Jason Richmond
Domtar	Hendrick Family Foundation	Drew and Shelley McCandless	Richmond County Savings Foundation
Don C. and Diane S. Lake Family	Heroes Inc.	The McCarthy Family	Riemer & Braunstein LLP
Don Miller Subaru East	Highmark Blue Cross Blue Shield and Allegheny Health Network	McKenney's, Inc.	Steve Rigby
Don Miller Subaru West	Hogan-Rutherford Inaugural Committee	Melryder Foundation*	William and Lynne Rogers
Donnelley Financial	The Howard Hughes Corporation	Memorial Healthcare System	ROMA Charitable Foundation
Marian Dozier	Huntsman International LLC	Memorial Sloan-Kettering Cancer Center	Robert and Nancy Rosen
Edith M. Schweckendieck Trusts	IBC Bank	Daniel Mendez	Steve Rosen
Edward G. & Kathryn E. Mader Foundation	Infor Global Solutions	Merck & Company ©	RPM Pizza (Domino's Pizza)
Edward Jones	Intermountain Healthcare	Steve and Ellen Miura	Daniel and Susan Ryan
EFESTÉ	J.P. Morgan Charitable Giving Fund	MKJ Communications	Samlyn Capital LLC
Eli Lilly and Company	Jane and David Jackson	Monumental Sports & Entertainment Foundation	Sanofi Genzyme
Emerson Charitable Trust	Michael and Jane Jamieson	Robert Moore	Save the Fox Foundation
EMI Research Solutions	JE Dunn Construction	Morguard	Arlene Schafer
ePLUS Technology, Inc.	Jerome S. and Grace H. Murray Foundation	MSS	Drew and Donna Schwartz
Erie Insurance	The Jim Jacobs Foundation	Susan Munzer	The Sessions Firm
Mr. Ed Ewing	Jochum-Moll Foundation	James Murray	The Sevan Charitable Foundation, Inc.
EY	The John G. Rangos Sr. Charitable Foundation	Names Family Foundation	Irene and Fred Shabel
The Fama Family Charitable Fund	The Joseph and Catherine Johnson Family Foundation	New Signature	Faisal Shaikh
The Fernandez Foundation, Inc.	Josephine Johnson	The North Bay Cancer Alliance*	The Shapiro Family Foundation
Fietler Family Fund	Kaiser Permanente	Northside Hospital	Sharp 594, Inc. DBA / IHOP 594
Fight Like Hell Golf JAM	Karyopharm Therapeutics	Ochsner Health System	Shumaker, Loop & Kendrick, LLP
The Firstenberg Foundation	Kendra Scott	OHC & Jewish Hospital – Mercy Health	Floyd and Noreen Singleton
Florentine Camenisch Foundation	Tai-Yee Kiang	The Order of St. Benedict of New Jersey	Sinkula Investments, LTD
Florida Power & Light	Kilroy Realty Corporation	Oregon Oncology Specialists	Skanska
FMC Corporation	Peter and Laura Klekamp	Orlando Health UF Health Cancer Center	The Skynyrd Foundation
Forward Advantage Foundation Inc.	Gerry and Penney Klingman	Penn Medicine	SoCalGas Turkey Shoot
Foundation Medicine (®)	LDC Health & Safety	Pepsi	Southern Glazer's Wine & Spirits
Friends of Las Vegas Metropolitan Police Foundation	The Lipstein Family		Ryan Spain
Furniture Fair	Lockton Companies		Special Kids Network, Inc.
Mr. and Mrs. Chris Gallagher	Lodging Hospitality Management Corporation		St. Joseph's/Candler
Gallo Family Charitable Fund			Stand Together Music Festival
Garber Automotive Group			Strike
Jeanne Gardner			Sturgeon Electric
			SunTrust

SuperValu Inc.	\$10,000-\$24,999	Jean and C.E. Andrews	Diane Baylor
Sutter Health	101 Surf Sports	Anne Wilson	BB&T
Suvoda	43rd Annual Amusement Theme Park Conference	ANRAK Corporation	BBG of NKY
Michael Sweig	60Feet6 Foundation	Ansira	BCM One, Inc.
Target CW	Abacus Technical Services, LLC	Anthem	Be A Man Buy Land
TECO Energy	The Abatecola Foundation	Anthem Blue Cross	Mr. Edmund Beebe
Terumo BCT	Bruce Abbey	AON Corporation	Beltway Cleaning Services
Texas Instruments, Inc.	Sandy Abbott	Aon Risk Services	Bender Foundation, Inc.
Thunderbirds Charities	Linda and Tim Abell	Apex Foundation	Bender Insurance Solutions
Tigerflight Foundation	Accel	Apple	Christopher Benrud
Tilden-Coil Constructors Team KSmo	Accelerated Urgent Care	Arizona Public Service	Michele and Howard Berger
Todd Reed McClintock	Access Capital Foundation	APTO Solutions	The Bernal T. Chomeau Private Foundation
Research Foundation	Accord Healthcare, Inc.	Aptose Biosciences	Bernard J and Camille Cebelak Foundation
Tolero Pharmaceuticals, Inc. ©	ACE Family Foundation	Margaret Arakawa	Bernhard MCC
Tour de Court 2019	Acertitude	Arch-Con Corporation	Paula Berry
Travel Leaders Group	Ann Adams	Steve Armstrong	Beta Engineering California LP
Trevor Loughlin Foundation Inc.	Susan Adams	Phillip Armstrong	Laura and Steve Beuerlein
True North Studio	Michael Adams	Arnof Kearns Family Foundation	Deep Bharadwaj
Ultimate Software	Adaptive Biotechnologies	Donor Advised Fund	Bl Worldwide
UNC REX Healthcare	Adonel Concrete	Ascend Learning LLC	Bill Thomas Associates, Inc.
United Way of Greater Milwaukee & Waukesha County, Inc.	Advance Auto Parts	Ascension	Lisa Bilotti Foundation
UnitedHealthcare	Advanced Computer Concepts	Associated Credit Union	Biotechnology Innovation Organization
The University of Kansas Cancer Center	Aerotek	Assurant	Bird Road Subaru
University of Michigan Rogel Cancer Center	Aetna	Astellas	George Bishop
The University of Texas MD Anderson Cancer Center	Aflac	Asuragen, Inc.	BJ's Restaurant Foundation, Inc.
UPMC	Against the Storm Foundation	The Atlanta Foundation	Seth & Stacy Blackman Charitable Fund
Valero	Greg Ager and Dave Dolan	Atlantic Health System	Connie Blackmon
Valley Children's Hospital	AIG	Austin Hardware & Supply	Allen Blakemore
Larinda Van Groningen	Alaska Airlines Matching Program	Authentic	Angela Blank
VCU Health System	Michael and Melissa Alber	Avalere Health	Bloodworks NW
Venable LLP	The Albrecht family	AvalonBay Communities, Inc.	Blue Cross Blue Shield of Kansas City
Judith Von Seldeneck	Alexandria Real Estate Equities, Inc.	Avantor Sciences Foundation	Blue Marble Cocktails
Wafra Inc.	Alibaba Group	Aventri	Blue Water Financial Partners
Washington Gas Light Federal Credit Union	Allegion	Avera	Meredith Bluhm Wolf
Greg Weimer	Adam Allen	Avison Young USA Inc.	BMC
Ellen Weissberg	Pat and Debbie Allender	Baker Botts	Bob Rohrman Lexus of Arlington
Gloria Weissberg	Pat and Debbie Allender	Baker Hughes Foundation	Nancy Boeck
Mark Weissberg	Alliance RX Walgreens Prime	Baltimore Orioles	Alex Boggs
Wellmed Charitable Foundation	Alliant Insurance Services	BankSouth Mortgage	Janet and Logan Boggs
Wespac Construction Inc.	Allied Associates International	Banner MD Anderson	Boies Schiller & Flexner
Wet Willie's Management Corp.	Allmond & Company, LLC	The Bar LV	Kelli and Don Bonacci
William R. Rich Foundation	Amadeus North America, Inc.	The Barbara and William Rosenthal Family Foundation	Nicole Bond
James and Judy Wilson	AmCap Mortgage, LTD	Dr. and Mrs. William Barfield	Bootleggers' Bash
WiSC Enterprises	Amerant Bank	Maggy Barnaba	Booz Allen Hamilton
Anonymous (5 donors)	American Ambulance	George Barr	Kate and David Borowski
	American Punjabi Charity	Karl Barron	Boston Biomedical (PA)
	Golf Association	Adel Barry	Boston Consulting Group
	AMERICAN SYSTEMS	Bartlett Cocke General Contractors	Boston Properties
	Ames Construction	Michael Bartschat	Boston's Best Coffee Roasters
	Ami Onco Theranostics	Bath Fitter	
	Anadarko	Batteries Plus Bulbs	
	Anaheim Ducks Foundation, Inc.	BayCare	
	Dwight Anderson		

Bowen Engineering Corporation	Clint Capela	Cleary Gottlieb Steen & Hamilton LLP	Cushman & Wakefield
John Boyle	Capital Educators	Tommy Cleaver	CWCcapital
Melvin and Barbara Bradley	TJ Caplinger	Cleveland Home Title	D3 LLC
Brandywine Realty Trust	Mike Capone	James Clough	D'Agostino's Markets
Steven and Sandy Brannon	Carahsoft Technology Corp.	Clune Construction Company	Dalena Farms
Richard Braune	Carahsoft/Splunk	Coastal Wealth, A Mass Mutual Firm	Anil Damani
Breakthru Beverage	Carl and Henrietta Herrmann Family Foundation	Cobb Strecker Dunphy & Zimmermann, Inc.	Thuy and Mitch Dancik
Breeden-Adams Foundation	The Carl M. Freeman Foundation, Inc.	Coca-Cola	Dan's Supreme Supermarkets Inc.
Tom and Barb Bresnahan	Glenn Carlson	Christopher Cocores	Toni Dassenko
Briad Restaurant Group LLC	The Carlton Family Foundation	Cohn Family Foundation	David Herche Foundation
Bridge Investment Group	Dayton Carr	CohnReznick LLP	David P. Sheetz Foundation
Bright Funds Foundation	Carrington Charitable Foundation	Cole, Scott & Kissane P.A.	David Spence Cancer Foundation
William Brinton	Carrington Mortgage Services, LLC	The Coleman Foundation	Gareth Davies
Mr. and Mrs. Andrew Brock	The Carroll Family Fund	ColonialWebb	Edward Davis
Michael Brooks	Bente and Jim Carter	Columbia Capital, LP	Davis Polk & Wardwell
Preston Browder	Caruso Homes	Commonwealth Charter Academy	Jim and Elaine Day
Morris Brown	Casino M8trix	Community Blood Center/Community Tissue Services	Michael de Vere
Brown Gould Kiely	Castro & Company, LLC	Community Foundation of Acadiana	Debbie J. Johnston Charitable Fund
Brown, Gibbons, Lang & Company	CBIZ	Community Foundation of New Jersey	Paul DeBruce
Rhonda and Jim Brunjak	CBS Corporation	Community Health Charities of Texas	The DeBruce Foundation
Craig Bryan	CC Residential Construction	Community Medical Centers	Ms. Deborah DeCotis
Buch Construction, Inc.	CDW	Compass	Dekker/Perich/Sabatini, Ltd
Kenneth Buesch	Centennial Technologies	Compco Industries	Erica Dekko
Buffalo Rock	Centerfield Media	Computer Design & Integration	Del Camp Investments Inc.
Buffalo Wild Wings	Central Carolina Community Foundation	Robyn and Don Conlon	Deloitte & Touche
Buis Family LLC	Cerner Corporation	Agnes Connors	Deltek Inc.
Bullock's Deli	Cetera Financial Group	Continental Resources, Inc.	Jamie DeMore
Jeremy Burge	CFC	David and Ashley Coolidge	Dennis Investments LLC
Burke Family Foundation	Christine Cha	Nelson and Dina Cooney	Dennis Nill Memorial Fund
Burlington Ventures	Darrell Chambliss	Jack G. Cooper	Derrel's Mini Storage, Inc.
William Burns	Changing Our World	Copper River Shared Services	Desert Institute for Spine Care
Burns & McDonnell	Charles Foundation	Cord Blood Registry	Susan DeVore
Jennifer and Jeffrey Butler	Charlie Tippman Foundation	Corduro	Dewey & Sons, Inc.
Thomas Butler	Charlotte Radiology	Judith Cosentino	Dewey Acres
Butler Family Foundation	Chiaromonte Construction Company	CoStar Group	Diane's Dream Charity
BVK	Daniel Chien	Patricia Cothran	Richard Dickinson
Dr. John Byrd	Children's Healthcare of Atlanta	Courtney Knight Gaines Foundation	Uribe Diego
C. Jay Moorhead Foundation	Choate Construction	Cox Automotive / Manheim / V Auto / VIN Solutions	Sharon and Paul Dillon
C.H. Robinson Worldwide	Betty and Don Chrisman	Cramer-Kasselt Advertising	Dimension Data
Caesar's Enterprise Services	Joseph Christianson	Crane U	Dippin' Dots LLC
Caesars Foundation	Theresa Christie	Credit Suisse Americas Foundation	Discover Financial Services
Tre Cage	Justin and Pauline Chueh	Cromar Foundation	Dittmar Company
Judy Cain	Cigna Healthcare - Carolinas	CroppMetcalfe Services	Diversified
Caliber Collision	CINJ	April Crosby	Diversified Restaurant Holdings, Inc.
California Coast Credit Union	Esther Cirelli	CrossCountry Consulting LLC	DLA Piper LLP
The Calys Family	Cisco Systems	Cross Country Healthcare, Inc.	DLT Solutions
Mr. and Mrs. Rohn Campbell	Citizens Bank - MA	CSI Leasing	Donald Palmer Charitable Fund
Renzo Canetta	Jay and Susan Clark	CSM Financial, LLC	Donald W Wallace and Erika® Wallace Family Foundation Inc.
Diane Cannato	Clearlink		Donegal Insurance Group
Lewis Cantley			Donna and Marvin Schwartz Foundation
Samuel Cantor Foundation			
Cantor Fund			

Nichole and Todd Doro	Kathleen and Bruce Eisey	Frederick and Margaret L. Weyerhaeuser Foundation	Gonsoulin Charitable Trust
Dorothy D. Smith Charitable Foundation	Bob Emery	Freeman Foundation, Inc.	Dr. Joseph Gonzalez
Doterra	Endeavor Real Estate Group	Freepoint Commodities, LLC	Good Samaritan Medical Center
Doug Schlegel Charitable Foundation	Energy Alloys, LLC	Maurice Friedman	Google
Dougherty Family Foundation	Enterprise Holdings	Roberta Frisch	GovSmart
Doylestown Health Cancer Institute	EOG Resources	Froedtert & the Medical College of Wisconsin	Grainger
DPR Construction	Epic	Fugus International	The Grainger Foundation
Dr. Gerald and Paula McNichols Family Foundation	Epizyme	Tracye Funn	Grane Rx
Tiffani Drake	The Epstein Family	Vijaya Gadge	Great American Insurance
Robin Driscoll	The Eric Scherbarth Leukemia Research Foundation	Gilles Gade	Greater Houston Community Foundation
Drive Social Media	Ernest & Irene Pestana Charitable Foundation	Maria Gaffney	Robert Greeley
DRTDA	Ernst & Young, LLP	Galen College of Nursing	Eric and Rachel Green
Dudley Family Foundation	The Escher Foundation	Sameer Gandhi	Greenberg Traurig
Duff & Phelps, LLC	Estate of Joe Cathcart	Garden Homes Fund	Greenstein Delorme & Luchs, P.C.
Duke Cancer Institute	Estates of Stoneridge Community, Inc., c/o Terrell & Amelia Gates	Gardner Business Media, Inc.	George Gresham
Duke Family Foundation	Gail Ewing	Bernard and Ethel Garil	Terie Gresham
Thomas Dunham	The Ethel and Harry Reckson Foundation, Inc.	T.H. Garner	James Gresik
Dr. Thomas and Mrs. Barbara Dunham	EXIT Realty Corp. International	Terrell Gates	Greystar Development, LLC
Laura DuPont	Exotech, Inc.	John Gayle	Group1001
Dorothea Durig	Express Scripts, Inc.	David Gaynoe	growth[period]
Dynasty Building Solutions	EY Philadelphia	Gelia, Wells & Mohr, Inc.	Gruenberg Kelly Della
E. & J. Gallo Winery	Fareway Stores	Gene and Jerry Jones Family Foundation	David Grunenwald
The Earl and Brenda Shapiro Foundation	Janet Faulkner	Leslie Geneen	GS Humane Corp.
Janie Earng	FD Stonewater	General Dynamics Mission Systems	Caroline Guerriere
Eastdil Secured, LLC	The Feighner Family Foundation	Gensler	Ronald Gula
Deane Eastwood	Edward Fein	Jim George	Gwatney Buick GMC
Eaton and Margaret Scripps fund of the Miramar Charitable Foundation	Richard Fennell	The George & Margaret McLane Foundation	Haley Garcia Group
ECCO Select	FFC Investments of Raymond James	George and Mary Josephine Hamman Foundation	Halliburton Foundation, Inc. (RM)
Eckert Seamans Cherin & Mellott, LLC	Fidelity Charitable	The George F. And Myra Shaskan Foundation, Inc.	Kathleen Ham
Ed & H Pillsbury Foundation	Findlay Automotive Group	George L Shields Foundation, Inc.	Hamilton Casework Solutions
Ed Morse Automotive Group	First Data	The George Link Jr Charitable Trust	Ms. Suzy Hammond
Edith Stoner Foundation	First National Bank of Long Island	GetWellNetwork, Inc.	Fred and Cherie Hand
Edrington Americas	Marcus Fischer	Shiva Ghahremani	The Handlery Foundation
Edward and Carol Miller Charitable Gift Fund	Flatstick Pub, LLC	Saman Ghahremani, M.D. P.C.	Audrey Hanken
EGF Charitable Fund	Mr. and Mrs. Jeff Floeck	Gilbane Building Company	Amy Hannah
EGF Charitable Fund c/o Isabel Welland	Florida Crystals Corporation	Peter Gilbert	Harder Mechanical
The Eli and Edythe Broad Foundation	Flushing Bank	Gillman Subaru Southwest	Price Harding
Elite Development, Inc.	FM Services Company	Ginkel Family Fund	Ronald Hardy
Ella B. Cleveland Trust	Foglia Family Foundation	Steven Glaser	Harkins Builders, Inc.
Elliott Davis	Force 3, Inc.	Lauren Glass	Janet and John Harper
Sabrina and Scott Ellis	Forgione Family	Global Payments Inc.	Janet Harper
Elmwood Hospitality LLC	Foundation for Impact on Literacy and Learning, Inc.	Global Traveler Magazine	Mr. and Mrs. Christopher Harris
The Elpis Foundation	Four Seasons Hospice	Linda Glover	Harris Construction Co., Inc.
	Fox 5	GM Financial	Harrisburg University of Science and Technology
	Fox Chase Cancer Center	Rebecca Godchaux	Harry S. & Isabel C. Cameron Foundation
	Fox Corporation	William and Simone Godshall	Donna Hartman
	Frampton Construction	Golfers vs. Leukemia	Bill Hartz
	Dianne Franco		Harv's Metro Car Wash
	Frank C. Diener Foundation		The Harvey E. Najim Family Foundation

Ray Haupt	Niles and Ginger Hushka	Nelul Jose	The Kolter Signature Homes
Michael and Sophie Hayes	Mr. Peter Huynh	Joseph Family Foundation	Koppers Railroad Structures
HCA Midwest and Sarah Cannon Cancer Institute	Hy-Vee	The Joseph R. Daly Foundation	Kevin Kordsmeier
HealthCare Partners	ICIX	Nancy Josephs	Thomas Kornei
HealthONE	ICON Building Supplies, Inc.	JRI Restaurant Holdings LLC	Bob and Jenny Kottler
Peter Hearn	ID Experts	JS Capitol Group	Marc Kovar
Heartland Express	IDI Consulting	Karen and Donald Jubel	Ray Kowalik
Randy and Nancy Hecht	iManage LLC	Jude's Gifts	John Kriendler
Robin Heckenliable	immixGroup	Judge Technical Services Inc.	Charles and Geraldine Kriser
Hedinger Family Foundation	Vincent Immordino	The Julius Family Foundation	Steven and Lisa Kristel
Holly Heer	Immucor Gamma	The June and Cecil McDole Charitable Fund	The Kroll Family Foundation
Bill Heer	Immunogen ^(PA)	K Machine Industrial Services	Dave Krosky
Gayle and Jeff Helman	In Care Of Hope	Gerald Kafka and Rita Cavanagh	Labor Foundation for Union Workers
Helsinn Therapeutics, Inc.	Incyte Corp	Sandra and Stan Kahan	Laborers' Local 190
John Hendley	Independent Health	Ari and Genelle Kahan	Ladish Co. Foundation
Hendrick Subaru Southpoint	Independent Trust Company	Kaiser Orange County	Lake Family Foundation
Henkels & McCoy	Indiana Reclamation & Excavating, Inc.	Soumya Kalahasti	Lalezarian Properties
Wanetta Henry	InfraSource LLC	Andreas Kalisperis	Jay and Kelley Lamy
Henry J Lee Distributors	Insulators International Health	Anne Kanelopoulos	Hilaire Lanaux Jr.
Rich Heppe	Hazard Fund	Kasasa	Bob Lanphere Jr.
The Heritage Group	International LLC	Kayleen Larson Legacy Foundation	Latitude
Larry and Tammy Hershfield	IPA Foundation	Mary Beth and Christopher Kearns	The LaVerna Hahn Trust
Hewlett Packard Enterprise (HPE)	IR TUA J & E SPEAS MEMORIAL	Keck Medicine of USC	Lisa Lawin
Donnie and Marcy Hill	I.S. 281 Joseph B Cavallaro	Keeler Motor Car Company	Ross Lawrence
Himan Brown Charitable Trust	Rodney Ivy	Annie and Kevin Kelly	Sheri Lawrence
Sam Hirbod	Jack Buncher Foundation	Kelly Floor LLC	Melanie Layer
HITT Contracting Inc.	Jack Henry & Associates	Carrie Kemper	Dr. Hillard M. Lazarus*
Rick Hoagland	Jack Seiler Farms	William and Diane Kenney	Douglas Lebda
Hobbs Family Foundation	Steven and Catherine Jacob	Daryl Kenningham	Dean Leber
Arline Hoel	Jane Wilson and David Mayhew	Kent Island American Legion Post No. 278	Dr. N. Ray Lee
Christian Holden	Stone Charitable Trust	Richard and Gloria Kerns	Jeffrey Lefcourt
Holder Construction Co.	Janus Henderson Investors	The Kerr Foundation	Lehigh Valley Health Network
Holistic Financial Partners	Brian Jaramillo	Armen Khadiwala	Leon S. Peters Foundation
Holland & Knight LLP	JBG Smith	Zahra Khaghani	Leukemia 24/7
Aaron Hollander	Jeff Paul Custom Homes	Kieb Foundation	Don Levin
Holy Cross Hospital	Jerry's Enterprises, Inc.	Susan Kilsby	Levine Financial Group LLC
Home Furnishings Representatives	Jewish Federation of Cleveland	King & Spalding	Lightning Community Hero
Guild of Southern California	Jim Koons Automotive Companies	Kings Point Trust	Linklaters LLP
Chris Hopkins	Doug and Kristen Johanson	Mr. and Mrs. Steve Kirby	Lion Group, Inc.
Horizon Pharma USA, Inc. ^(C)	John & Margo Simons Foundation	Kirkland & Ellis	The Lipman Family
Casey Horoho	John Albuerne Family Foundation, Inc.	Emily and Neil Kishter	Michelle Little
The Hossein & Guitty Ejtemai Foundation	John and Mary Franklin Foundation, Inc.	David Klapper	Lois and Richard England Family Foundation
Greg Hostetler	John Moriarty & Associates of Florida	Kleinberg Electric	Houlihan Lokey
Robert Hottman	The John Newell Wade Foundation	Kleinschmidt Family Foundation	Long John Silver's/A&W/KC Mavericks
Houston Methodist Hospital	Emery Johnson	KLS Public Strategies LLC	Suzanne and Albert Lord
Tracy Howard	Dan and Cindy Johnson	Rochelle Klutch	The Lotz Family Foundation
Hoxworth Blood Center	Johnson Operating Account	KMDI, Inc.	Lou Fusz Subaru
John and Jeanne Hubbard	Jones & Frank	Karen Kocher	Louisville Metro Government
Hughes Enterprises on NJ	Jones Lang Lasalle Americas	Michael Koester	Lowenstein Sandler LLP
Greg Hunt		Kohl's Cares	Bruce Lowthers
Hunt Construction Company		Kolache Factory	

Tami Luhby and Ed Purce	Medspace	Muha Family Foundation	OK Realty King
LuJac Construction Services LLC	MedStar Georgetown University Hospital	Murdock Auto Team	O'Keefe Lyons & Hynes, LLC
Kent Lynch	Seth Meisel	Patrick Murphy	Okta
M2Gen	Mel Hambelton Ford, Inc.	Murray and Guari Trial Attorneys	Olivia Hope Foundation
M7 Aerospace	Memorial Health	Myron H. Ackerman Trust	Olympian Construction Company
M9 Charitable Fund	Michael Mena	n2grate	Omega Wealth Partners
MacArthur Foundation	Jhonny Mercado	The Nakamoto Family	The Omer Foundation
Macy's	Merck	Leslie and Larry Nance	Once Upon A Child
George Macon	Mercy Health	NASA Federal Credit Union	Oncology Care fund
Vanessa and Sean Magee	Mercy Hospital	National Foundation for Affordable Housing Solutions, Inc.	Elton O'Neal
Kristen and Marc Magod	Meritor, Inc.	National Information Solutions Cooperative	Optuml
Gerard and Joyce Magrini	Merlin Wealth Management at Morgan Stanley	The Navarrete Family	Oquirrh Hills Middle School
John Maine	James Merrifield	Navarro Family Foundation	Oracle
Maine Family Fund	Merrill Lynch	Navigant	Cathy Orrico
Major Hyundai	Andrew Meslow	NC Electric Cooperatives	Dan O'Sullivan
Charles Malk	MHAWorks	Nebraska Medicine	Ourisman Chantilly Imports, Inc.
Mallinckrodt Pharmaceuticals 	The Michael Treinen Foundation	Nehemiah Manufacturing Company	Mr. and Mrs. Brett Overman
Malloy Toyota	Robert Michaels	Neshaminy Electrical Contractors Inc.	Pacific Service Credit Union
Mammoth Energy Partners	Microsoft Matching Program	Ness Digital Engineering	Gail and James Palmer
Manatt, Phelps & Phillips, LLP	Midwest Clothiers LLS	Nestle Purina PetCare Co - Gateway	Papadopoulos Family Foundation
Craig Manske	Miles & Stockbridge P.C.	New York Community Bank	Parisi & Havens LLP
Marilyn and Larry Margolis	Dean Miller	New York State Troopers PBA Signal 30 Benefit Fund	Mr. and Mrs. Howard Parker
MaritzCX	Natalie and JT Miller	Timothy William Newman	Parkview Cancer Institute
The Marksmen Company	Miller Paint Company	Matt Newsom	Parkview Physicians Group
Mary P. Sterling Foundation	Miller Pipeline	Bonni Newton	Alyssa Parrish-Bublewicz and Michael Bublewicz
Marylou's Coffee	Miller Street Dance Academy LLC	NewYork-Presbyterian	Mary Parsons
Masonic Charities of Delaware	Joseph Milton	Andrew Nibley	Partners Surgical LLC
Mass General Cancer Center/ Inpatient Unit	MM Finance LLC	Kelly and Bradley Nicklin	Kris Patel
Russell Masters	MN, ND, SD Chapter Board of Trustees	NOCO Energy	Patriot General Engineering, Inc.
Frank Mattei	MobileCause, Inc.	Noco Express LLC	Sara Patterson
Deryck Maughan	Modus Direct	Mr. and Mrs. Phillip Noel	Jerry Neil Paul
Maverick Capital Foundation	Mohawk Honda	Northeastern PA Health Care Foundation	Paul B. Greetin and Beryl S. Greetin Foundation Inc.
Janet May	Christina Mohr and Matthew Guerreiro	Northrop Grumman	The Paul E. Singer Foundation
MB Financial Bank	Niels Moleiro	Northwell Health Cancer Institute	Paul, Weiss, Rifkind, Wharton, Garrison Charitable Fund
Jacki McAneny	Montefiore Medical Center--Oncology	Northwestern Mutual--Minneapolis	Pegula Sports & Entertainment
Sarah McClelland	The Moore Family	Norton Rose Fulbright US LLP	Penn Station East Coast Subs
McCownGordon Construction	Morgan Stanley	Nova Home Loans	PEP Promotions
Mr. and Mrs. Henry McCrary, Jr.	Morgan Stanley Global Impact Funding Trust, Inc.	Novak Family Foundation	Pepsi Portland
Mike McDonald	Bob Moritz	NV5, Inc.	Rey Perez
Erin and Mark McFarland	Mortenson Construction	Oakland Athletics	Performance Automotive Network
Amy and Ryan McGinnis	Mother Murphy's Labs, Inc.	Oates Family Foundation	Mr. and Dr. Kelly Perkins
Mr. and Mrs. Sean McGould	Mountain America Credit Union	Donald Obrecht	Mr. and Mrs. Scott Perkins
Mr. and Mrs. Shaun McGruder	Mountain West Investment Corp.	John and Cynthia Occhipinti	Marla Persky and Craig Heberton
McLean Mortgage	Movement Foundation	Oconee Capital Investments, LLC	Donita and Sheldon Petersen
William McNitt	Mr. and Mrs. Stephen Movius	Lydia and Robert Odle	Matthew Peterson
MD Anderson Cancer Center at Cooper University	Mr. Hero	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	Ms. Melissa Peverini
MDC/Richmond American Homes Foundation	MSA Design		PGA TOUR Superstore
Medallion Foundation	MTS Health Partners LP		Philadelphia Sign
Medical Mutual			PhRMA
Medidata			Steven Pidgeon
Medpace			Pietro's Restaurant Group, Inc.

Pike Electric
 PJLowa, LLC
 Planet Fitness
 Platformq Health, Inc.
 Eileen and Gerald Poblocki
 Kim and Nick Pomponi
 Pondurance LLC
 Scott Poole
 Porsche North Scottsdale
 Porsche of New Orleans
 Porter Hedges LLP
 Portland General Electric
 Powell Industries
 Praxair
 Precision Biosciences, Inc.
 Precision Lender
 Press Ganey Associates
 Mr. and Mrs. Jeff Preston
 Mr. and Mrs. John W.S. Preston
 Prometheus Partners
 The Puente Family
 Charline Pulizzi
 Pure Storage
 Quest Diagnostics
 Quicken Loans
 Quorum Software
 R. G. Miller Engineers
 The Rabbitt Whalen Family
 Foundation
 Elizabeth Raleigh
 Barbara Rapaport
 Raymond James
 Dorine Real and Lee Tepper
 Real Estate One Foundation
 Ms. Kimberly Reckley
 RED Capital Group
 Red River Technology
 Jason and Heather Redpath
 Regal Foundation
 Regatta Network
 The Reinalt-Thomas Corporation
 Randy and Debbie Rehmman
 Andrea Reid
 Adam Reinhardt
 Mr. and Mrs. David Rendina
 Mrs. Marjorie Rendina
 Mr. and Mrs. Richard Rendina
 Resilience Capital Partners
 The Rhoda and David Chase
 Family Foundation, Inc.
 Polly and Gregg Ribatt
 Joe Ricciuti
 Mr. and Mrs. Troy Rice
 Richard M. Schulze Family
 Foundation
 Rifenburg Construction
 RMD Investors
 Steve Robert
 Robert J. Healy Elementary
 The Robert R. Sprague Foundation
 The Roberts Family
 Roberts Oxygen Company, Inc.
 Doug Robinson
 Mr. and Mrs. John W. Robinson III
 Gene Rochlin
 Rock the Campus
 Rockefeller Group
 Rockland's Greatest LTD
 Rocky Mountain Cancer Centers
 The Roderick Seward, Flossie
 Radcliffe and Helen M. Galloway
 Foundation, Inc.
 Bonnie and Sam Roditti
 Rotary Club of Nashua West
 Rottendorf Pharma, Inc. ©
 Mary Rowan
 RSM
 Keitha Russell
 Roger Russell
 Ruth Robinson
 Jason Ryan
 David Ryle
 Robert & Barbara Sablowsky
 Foundation
 Jeffrey and Catherine Sachs
 Safeway
 The Safeway Foundation
 SailPoint Technologies
 Salinas Valley Memorial
 Healthcare System
 Niki Salter
 Salzman Hughes, P.C.
 Sam J. Frankino Foundation
 Sam's Club
 The Samek Law Firm
 San Diego Sign Company
 The San Francisco Foundation
 San Jose Earthquakes
 SAP Concur
 SAP NS2
 Sarah Tarditi Gallagher Memorial
 Golf Outing
 John Saunders
 Mr. and Mrs. Mark Saur
 Savannah Chatham Imaging
 Sawnee Electric Membership
 Foundation Inc.
 Joel and Natalia Saxton
 Anthony Scaramucci
 The Schaufeld Family Foundation
 Scheid Family Wines
 Laura Schlegel
 Brian and Sandra Schneider
 Schnucks Markets, Inc.
 Schorr-Lieberman Family
 Foundation
 Schumacher Construction
 Management, Inc.
 Charles Schwab
 Robert and Jennifer Schwing
 Helena Scott
 Scotts Valley High School
 Scripps Green Hospital
 SDS Restaurant Group LLC
 The Segerstrom Foundation
 Paul Seipp
 Mark Seltzer
 Sendero Midstream
 Servier Pharmaceuticals (PA)
 Carl Sewell
 Sewell Automotive Company
 Seyfarth Shaw LLP
 Samuel Shaheen
 C. Kevin Shannahan
 Sharp 471, Inc. dba / IHOP 471
 John Shaw
 Bill and Diane Shaw
 Jere Shawver
 Shepherd's Chevrolet Buick GMC
 Sherwood Forest SC
 Douglas and Barbara Shindler
 Matthew Shirah
 Kevin Shivers
 John and Marcia Shooshan
 Shopright Supermarket of
 Cherry Hill Inc.
 R.L. Sias
 Bart and Linda Sichel
 Sidley Austin LLP
 The Sidney, Milton and Leoma
 Simon Foundation
 Sidney Kimmel Cancer Center at
 Thomas Jefferson University
 Michael Siegel
 Silicon Valley Community
 Foundation
 Silver State Schools Credit Union
 Mr. and Mrs. Robert Simmons
 Simplot Food Group
 Neal Simpson
 Simpson Thacher
 Dwight Sipprelle
 Sirius
 Site Master
 Skoda Contracting Co., Inc.
 Charles and Meg Slater
 The Sleep Family
 Brad Smith
 Douglas and Phyllis Smith
 E. Smith
 Jeff and Marnie Smith
 Kristie Smith
 Lester Smith
 Mack Smith
 Michael Smith
 Michael L. Smith
 William Smith
 Hermine Soler
 Sonic Automotive
 Southeastern, Inc.
 Southgate Glass
 Southwest Local School District
 Bonnie and Stephen Spiegle
 Spire, Inc.
 H. Mark Sponseller
 Springfield Pancakes, Inc.
 IHOP #4509
 St. David's Healthcare
 St. Juste Management Corp.
 Robert Stall
 Gretchen Stangier
 Star Anesthesia, PA
 Statewide Restoration
 Barb and Tom Stayton
 Steel Dynamics Inc. & Keith Busse
 Enterprises
 Kevin K. Steiner
 Stemline Therapeutics
 Jon Sterling
 Jeffrey Stern
 Steward Family Foundation
 Stifel Financial
 Mr. Kenny Stiles
 Stirista
 Stoller Family Foundation
 David Stone and Aileen Karstofsky
 Kristin Stork
 Strategic Education, Inc.
 Strategic Site Development, LLC

Strikes Against Cancer
 Studemont Group
 Sub Pop Records
 Suez Water Technologies and Solutions
 Tim Sullivan
 Sullivan & Cromwell LLP
 Summit State Bank
 Superior Subaru
 Supermarket of Cherry Hill
 Supermix Concrete
 Steven Suttle
 Andrew Sveikauskas
 Mr. and Mrs. Jack Swan
 Mr. and Mrs. Rob Swan
 Swedish Cancer Institute
 Sykes Enterprises
 Symantec Corporation
 SYNEX Corporation
 Sysco Corporation
 Bettyann Szotak
 Tampa Bay Buccaneers & Manchester United F.C.
 Tampa Bay Lightning
 Tampa Bay Rays Baseball
 Ann Taylor
 TD Bank
 Team Kirsten
 Tee It Up to Cure Leukemia – Jana & Warren Brickey
 Tellabs
 Terakeet LLC
 Terry D. and Carol A. Agnes Charitable Trust
 Texas AirSystems LLC
 Texas Oncology
 Terri Theisen
 TheHouse.Org
 Thiesen Dueker Financial Consulting Group
 Thomas and Agnes Carvel Foundation
 Thompson Habib and Denison
 Thornton Tomasetti, Inc.
 Tito's Handmade Vodka
 Joshua Titus
 TJX Foundation, Inc.
 TKTMJ, Inc.
 T-Mobile
 Tolero Pharmaceuticals
 Tom & Virginia Jennaro Family Foundation, Inc.
 TomTom North America
 Tooley Oil Company
 Jay Torborg and Diana Dickinson
 Toyota
 Trademark Title
 Transwestern
 Travel Resorts of North Carolina, LLC
 Kari and Greg Trayer
 Treen Events
 Trent & Teresa Jackson Family Fund
 Triangle Oktoberfest Rotary Foundation
 TriHealth
 Trust Company of the South
 Eddy Tsang
 Albert Tsui
 Tullett Prebon Americas Holding
 Jill Turner
 Turner Construction Company
 William Tutwiler
 Barbara Tyson
 U.S. Chamber Of Commerce Foundation
 UAB Medicine
 UAW Ford Flat Rock Assembly Plant
 UBS Financial Services Inc.
 UCLA President's Fund
 UK HEALTHCARE
 Unanet
 United Capital
 United States Marine, Inc.
 United Therapeutics Corporation
 Universal Electric Corporation
 The University of Arizona Cancer Center at Dignity Health St. Joseph's Hospital
 The University of Chicago
 University of Southern California
 Upchurch Kimbrough, LTD.
 US Bank
 UTSW Simmons Cancer Center
 VAE
 Natan and Beth Vaisman
 The Valente Foundation
 Valley Electric
 Value Pay Services
 Deanna Van Gestel
 Vanda Pharmaceuticals Inc. 
 Vanguard Charitable Fund
 VCC, LLC
 Julie and Phil Venables
 Phillip Venables
 Verastem
 Versiti, Inc.
 Lela Vickery
 Vida Global Foundation, Inc.
 Virginia Friedhofer Charitable Trust
 Virginia Sheldon Jerome (VSJ) Foundation
 Vita Coco
 Carol and Thomas Voss
 The W. O'Neil Foundation
 Christian and Lina Waage
 Wall Family Enterprise, Inc.
 The Wallace Fox Foundation
 Walmart
 Walter Johnson High School
 Julianne Ward
 WARNERMEDIA
 Washingtonian Magazine
 The Washington Redskins
 Waste Connections, Inc.
 Water Utility Management Company, LLC
 WB Engineers+Consultants
 Maureen and Doug Webster
 Weill Cornell Medical College
 David Weinstein
 Robert Weismantel
 David Welland
 The Wellmark Foundation
 The Werther Family
 Western & Southern Life
 Western Digital Corporation
 Western States Council Leukemia Fund
 Whirley-Drink Works
 The Whiting-Turner Contracting Company
 Todd Wigfield
 Sherry and John Mark Wilhite
 Willco
 William and Margaret Schreiber Foundation
 Willamette Valley Bank
 Douglas Williams
 Thomas Williams
 Williams Realty & Building Company, Inc.
 Patricia Willson
 WilmerHale
 Wilmington Trust
 Ann Wilson
 Andrew Wilson
 Winnsboro Petroleum Company
 Winwood Children's Center
 Nancy Wolfe Lane
 Glen Wolther and Donna Rosen
 Womble Bond Dickinson
 Woody Woodall
 Woodforest National Bank
 Jerry Wordsworth
 World Bank Group Community Outreach Program
 World Travel Holdings
 World Wide Technology, Inc.
 John Wright
 Howard Yang
 Yokohama Tire Company
 Yoslov Family Foundation
 Young Conaway Stargatt & Taylor, LLP
 Sherry Zander
 Cathy and Scott Zeilinger
 The Zenith Insurance Company
 Zinkin Family
 Zotec Partners, LLC
 Zurich American Insurance Company
 Joseph Zvesper
 Zyedge
 Anonymous in Honor of Diane
 Anonymous (9 donors)

Top Campaign Fundraisers

#NoMoreNames
 614aCure
 A Cure for Stella
 Evelyn Akers
 Al's Angels
 Mackenzie Aladjem
 Aladjem's Angels
 Grant Albin
 Lauren Alff
 Allison Shapiro's Campaign Team
 Allyson Spring's Campaign Team
 Teresa Altemeyer
 Alyssa Parrish's Campaign Team
 Amanda Baltz's Campaign Team
 Amazing Grace
 Tamara Amini
 Anthony Maslow's Campaign Team
 Archmere Academy
 Armen Khadiwala's Campaign Team
 Dr. Jess Armor
 Curtis Arnold

Lynn Aronberg	Scott Bores	Christine Clawson's Campaign Team	Derek Miller's Campaign Team
Ashley Havera's Campaign Team	Boston Creates Hope	Joe Ciccarelli	Joseph DeSabia
Daniel Atamanchuk	Boston Reunion Team	Circle of Hope Campaign Team	Yash Desai
Sherrie Austin	Rod Bowe	Esther Cirelli	Eric Dewey
Paige Babbs	Bowe's Blood Brigade	Sarah Cirelli and Team Bad Blood	Katherine DeWulf
Richard Babineau	Blair Bowen	City of San Antonio	Discount Tire
Phylliss Bailey Brooks	Brad Stinson's Campaign Team	Christine Clawson	Bygie Dixon
Beau Baker	Lily Brady	Ben Clinkenbeard	Dominic Tully's Campaign Team
Kelly Baker	Gayle Brand	Jamie Cobb	Karissa Dominick
Ginger Baldwin	Madison Breazeale	Adam Cohan	Bella Doro and Cheering for a Cure
Brad Ball	Jenn Brigle	Ryan Cohen	The Dream Team
Claudia Ballas Latch	Preston Browder	Meredith Coleman	Roya Ebrahimi-Qajar
Trae Ballinger	Jarad Brown	Colton's Army	Martin Einhorn
Amanda Baltz	Jennifer Brown	Compass Self-Storage, LLC	Eric Eissenstat
Bank of America	Kim Brown	Ava Connell	Elizabeth Greever's Campaign Team
Bank of America / Merrill Lynch	Tami Brown	Connell High School	Richard Ellin
Naader Banki and Team Iron Banki	Bryan Jansen's Campaign Team	Peter Connolly	Maya Ellison
Barclays	Bryce Unger's Campaign Team	Constance Howlett's Campaign Team	Eric Dewey's Campaign Team
Jessica Barnett	Bulldogs Bite Cancer	Kelly Cook	Eric Grossman's Campaign Team
Lauren Barr Jebesen	Joe Bunce	Gordon Cooke	Erica Pizzeck's Campaign Team
Sarah Barwell	Jessica Burgess	Josh Cooper	Erika Salinas's Campaign Team
Battle Brenna	Burlington Stores Corporate Office	Ken Corbett	Grayson Ertel
Louisa Bayburtian	Julie Buschman	Corts Girls Curing Cancer	Lauren Esposito
Bears Against Blood Cancer	Lucy Byer	Catherine Covell	Ethan & Sidney's Campaign Team
Erin Beasley	Avery Byrne	Chris Coxon	Lilly Evans
Jeri Ann Beckworth	John Calys	Leslie Coxon	Everett Fire Department
Holden Beecher	Camille Miura's Campaign Team	Bill Craighead	FAMILy
Rasha Beg	Camile Olivere's Campaign Team	Sera Cremona	Gary Farmer
Joanna Belt	Dee Campbell	Jenny Crow	Katherine Farmer-Thornhill
Ben Clinkenbeard's Campaign Team	Cancer Crusaders	Crusaders for a Cure	Jonathan Faust
Ben Fogel's Campaign Team	Cancer Crushers	Crusaders for a Cure	Sofia Fernandez
Ben Gerber's Campaign Team	Cancer is Wack - Blake Kelly, Christian Kelly, and Justin Emi	Joe Cupoli and Team Operation Hope	Ed Ferrell
Lynn Bennink	Cancers Answer	Cure Cancer Crusaders	Jack Ferruzzo
Pete Benoist	Mark B. Candelaria	Cure Collective	FIS
Jesse Bergland	Robert "Spider" Cantley	Daniel Dagit, Jr.	John Fitch
Chris Berlow	Can't Stop the Healing	Lindsey Dameshghi	Waring Fleitas
Reid Besch	Cardinals Cure Cancer	Lyndsey Danberry	Florida Power & Light
Darren Better's	Jim Carman	Dani Frisch Harkin's Campaign Team	Ryan Floyd
Michael Blackman	Carmen Harris's Campaign Team	Daniel Atamanchuk's Campaign Team	FoCo Cure
Blackstone	Bill Carteaux	Daniel Sullivan's Campaign Team	Ben Fogel
Laura Blanchard, PA-C	Carter's	Dara Spearman's Campaign Team	Megan Freas
Hudson Blass	CBH Homes	Darren Better's Campaign Team	Erin Freeman
Charles Blocksidge	Cetera Financial Group - Friends of Luanne Graham	David Arkoosh's Team	Freshman Knights
Bloomberg Marathon	Champions For A Cure	Lisa Davis	Delisi Friday
Bloomberg Spring Team	Charles Esten's Team Addie	Schaquil De Young	Friends for a Cure
BMC	Nischal Chennuru	Mario DeFrancesco III	Dani Frisch Harkin
BMC Triangle Market and Corporate Support	Sahm Cho	Daniel DeGuire	Bridget Fry
Emilia Boggs	Chris Townsend's Campaign Team	Delbarton School	Taylor Fry
Beau Bokelman	James Chrisman	Demitrius Puente's Campaign Team	Mina Garavi
Dr. Uma Borate and Team OHSU	Gabrielle Christie and Team Bring The Change		Lily Gardiner
			Virginia Garner
			Michelle Gaulding

David Gaynoe	Hendry's Heroes	In memory of Irene Christopulos and Donald Procida (Marisa Christopulos)	John Katsetos
Genevra Richardson's Campaign Team	Charlotte Henry	In memory of Joe Fitzgerald (Kate Fitzgerald)	Michael Katsock
Simon George	Herb's Chain Gang Powered by Kailie's Krew	In memory of Rami Zakhour (Firas Nassif)	Peter Katz
Ben Gerber	Hikers4Life	Joe Innacone	Jim Kaufman
Asaf German	Delaney Hill	InvinciBill	Micaela Keane
Noora Ghahremani	Rachel Hines	Jack Maine's Campaign Team	Keane on Beating Cancer
Frank Giampoli	Caleb Hinson	Trent Jackson	Ken Schwing's Campaign Team
Scott Gildea	Thomas P. Hogerty and Team Blood Brother	Ava Jambor and Noah's Army	Jennifer Kennedy
Gilman Lower School	Holden Beecher's Campaign Team	Denisse James	Brett Kessler
Girls for the Green and Orange	Eli Holder	Janine Ward's Campaign Team	Eric Kesti
Dylan and Zoey Glazer	Eva Hooten	Bryan Jansen	Armen Khadiwala
Jay Glunt	Robert Hope	Jason Smith's Campaign Team	Aamilah Khanu
Steven Goldstein	Hopeful Hearts	Jeffrey Rovner's Campaign Team	Kick Leukemia's Zaas
Stacy Goldstein	Tim Houterloot	Jen Thomas's Campaign Team	Kate Kilroy
Amy Golladay	Kelli Howard	Jennifer Brown's Campaign Team	Parker Kink
Frank Gordon	Tracy Howard	Jeremy Schwibner's Campaign Team	Chuck Kiven
Gordon's Groupies	The Howard Hughes Corporation	Jerni 4 a Cure	Kiven, Kotler, Lieberman, Fox, Goldschmidt, Kepes & Lev
Grace Toomey's Campaign Team	Constance Howlett	Jan Jernigan	Lance Knez
Graci Graves's Campaign Team	John Huber	Jessica Burgess's Campaign Team	Knockout Blood Cancer
Alex Graf	Katy Huie Harrison	Jessica Henderson - Funiestas's Campaign Team	Jhansi Koduri, M.D.
Graci Graves	Morgan Hunt	Jhansi Koduri's Campaign Team	Stanley Koehl
Maya Gray	Jonathan Hutton	Jim Kaufman's Campaign Team	Matthew Koff
Rick Gray	Lindsay Iadeluca	Wendy Jirsa	Koppers
Adam Green	Clayton Idle	Joe Maio's Campaign Team	Lee Korn
Green Tie Gala / Chuck Cuda	Renjitha Ignatius	John Huber's Campaign Team	Bob and Jenny Kottler
Douglas Greene	In honor of all who have battled Hodgkin's Lymphoma (Chris Saizan)	John McDonough's Campaign Team	KPMG Cycle
Karen Gresham	In honor of Bill Fores (Team 209)	Jhonny Mercado's Campaign Team	Kristen Krikorian
Eric Grossman	In honor of Caleb McNitt (Ride For Dads)	Nora Johnsmeyer	Kristen Meyer's Campaign Team
William Gruver	In honor of Cassidy Sidhu and in Memory of Lou Cole (Thea Campbell)	Andrea Johnson	Kristie Welte's Campaign Team
Ashley Gulledege	In honor of Firas Nassif (Taro Arai, Mikuni Charitable Organization)	Bert Johnson	Dave Kuba and Team Reality Fights
Ajay Gupta	In honor of Frank Amaral (Team 209)	Tracy Johnson	Jessica Kuba
Hala Ziady's Campaign Team	In honor of Garrett Heisinger (Team Cureageous)	Andrew Jones and Team Live Life Stronger	Michelle Kuhn
Brad Hall	In honor of Lisa Villamil (Team Living Victoriously)	Chris Jones	J. Marc Kurowski
Summer Hall	In honor of Mike Tooley (Team Tooley)	Lauren Jones	Max Landwirth
Nancy Hamlin	In honor of Omar Ali (Abdul Ali)	Jonesin' for the Cure	Lanphere Auto Group
Janet Ziegler Hanacek	In honor of Ryan Tooley (Team Tooley)	Julie Buschman's Campaign Team	Blair Larkins-Seyfried
Mark Hannah	In honor of Team Don't Stop Believing (Firas Nassif)	Julie McPherson's Campaign Team	Larry Treen Jr.'s Campaign Team
Katie Hanshaw	In memory of Bernice N. Zahn (Melvin Bradley)	Just Cure It – CTWHV	Lauren Esposito's Campaign Team
Stephen Haraden	In memory of Dennis Bravo (Team 209)	Just Cure It – Illinois	Lauren Rigg's Campaign Team
Carmen Harris		Just Cure It – NYC	Lauren Simione's Campaign Team
Denise Hartmann		Just Cure It! – Long Island	Emily LeBlanc
Ashley Havera		Just Cure It! – PHX	Katherine Lee
Marianne Heatherly		Just Peachy	Dr. N. Ray Lee
Jill Heineck		Lilly Kannapell	Chad Leteris
Jamie Heldt		Katherine Thornhill's Campaign Team	Lehigh Valley Circle of Hope
Kinsley Helmer		Kathy Pidgeon's Campaign Team	Elizabeth Lehr
Jeff Helms			Leslie Coxon's Campaign Team
The Heme Dogs			Tyler H. Lester
Jessica Henderson - Funiestas			Alanna Levine
Nance and Heather Hendley			Alexa Levine
Abbie Hendry Hammett			Valerie Lewis

Nadine Link	Heath Melton	Kritesh Patel	Caroline Roth
Tracy Link	Jhonny Mercado	Sachit Patel, MD	Jeffrey Rovner
Loree Lipstein	Laurie Merrick	Sara Patterson	Heath Rudduck
Michelle Little	Kristen Meyer	Sarah Paul	RumFront
Lynn Liu	Michael Magoon's Campaign Team	Pele's Pirates	Gabrielle Russo
Bernard Llave	Michael Riotto's Campaign Team	Peter Katz's Campaign Team	Daniel Ryan
Brittany Lofton	Michelle Little's Campaign Team	Pete's Posse	Ryan Cohen's Campaign Team
Loree Lipstein's Campaign Team	Michelle Ralph's Campaign Team	Kathryn Pidgeon	Ryan Morris's Campaign Team
Christie Ludwick	Jackie Milla	Dr. Bud Pierce	Will Sabayrac
Sauris Lugo	Derek Miller	Scott Pioneck	Sachit Patel, MD's Campaign Team
Lymphomaniacs	Jack Miller	Erica Pizzeck	Jon Sadler
Lynn Aronberg's Campaign Team	Sydney Miller	Jenny Pleasant	Sahm Cho's Campaign Team
Logan Maciejewski	Miller's Rogue Fishers	Plymouth Elementary School	Adria Salas
George Macon	Miracle Makers	Pop's Warriors	Salesforce
Mad Lion	Miracle Maya	Reese Power	Salesforce.com-"Boston Strong"
Dr. Michael Magoon	Mission is Possible	Libby Powers	Erika Salinas
Jack Maine	Camille Miura	Lauren Prenaveau	Neil Salvage
Joe Maio	Matt Mobley	Abby Price	Salvatore R Calabro
Iman Malhi and Nyari Muchaka	Xavier Momper	Demetrius Puente	Elementary School
Manuela Yanez's Campaign Team	Meghan Monahan	Christine Pullara	Tori Santos
Marc Kurowski's Campaign Team	Amanda Montell and The Lymphomaniacs	The Purple Pride Saves Lives	Sarah Paul's Campaign Team
Jailyn Marcel	Isabella Montero	PwC - NYC	Sarah Shirley Smackdown
Megan Marconyak	Jen Moog and Team #gameon	Aimee M. Quirk	Kimberley Sason
Margo's Marathon Maniacs	Antonio Moore	Leena Rai	James Savier
Marianne Heatherly's Campaign Team	Ryan Morris	Raise for a Cure	Jake Schlitt
Mario DeFrancesco III's Campaign Team	Kevin Morris	Rampart High School	Tommy Schroeder and Team
Richard Marquez	Stacey Moser	Kevin Raymond	FireFight Cancer
Sidney Marsh	Jake Mouton	Ryan Reilly	Schuyler Colfax Middle School
Brian Martinenza	Kelly Munyan	Tara Reilly	Martin Schweitzer
Jany Martinez-Ward	Patrick Murphy	Relentless Raiders	Ken Schwing
Anthony Maslow	Bridget Murray	Sarah Reuter	Helena Scott
Valerie Maslow	MWOYLA Leadership Committee's Campaign Team	Susan Rheingold	Scott Bores's Campaign Team
Colton Matter	My Girl	Genevra Richardson	Scott Paris's Campaign Team
Max Landwirth and Team #FromTheHeart	Drew Naiburg-Smith	Eloise Richter	Liz Sczudlo
Mayhul Patel's Campaign Team	Nathan Stallings's Campaign Team	Riders Of The Storm	SDG&E/Sempra
Kathy Mazzei	Geri Naumcheff	Will Rigby	Seattle Genetics
Drew and Shelley McCandless	Jim Newman, CPA	Lauren Rigg	Kevin Shannahan
Katey McCandless	Natalie Noss Handler	Carson Riley	Allison Shapiro Dandry
Mackenzie McCarter	Lindsey Noto	Michael Riotto	Mark Shay
John McDonough	NYC Alumni & Friends	Kenzie Robertson	Stacie Sheely
Dana McGinley	Chris O'Brien	Robin Thurau's Campaign Team	Kevin Shivers
Miles McLvaine	Greg Oldham	Annie Rose Robinson	Sophie Shumway
Gibson McKay	Camille Olivere	Mackenzie Robinson	Lauren Simione
Bill McKenzie	Scott Olmsted	Renee Robinson	Sisters By Blood
Hannah McNeal	Ellie Olshanski and Team Make a Difference	Rick Roby	Callie Skurla
Julie McPherson	On Board for a Cure	Rockin' Out Cancer	Smiles for Miles
Megan Freas's Campaign Team	Scott Paris	Will Rogers	Elizabeth Smiley and Team Smiley
Kimberly Meincke Jacobsen	Parker Kink's Campaign Team	Philip Roman and Jarrod Gans	Holden Smith
Forest Melton	Teeny Parks	John Romley	Kyle Smith
	Alyssa Parrish- Bublewicz	Sondra Rose	Jason Smith
		Steven Rosen	Serena Smith
		Bob Roth	Jared Smukler
			Sophia and Margot's Survivors

Kari Souers	Team Cure-aLLS	Nichole Theriault	Washington Gas - 10th Annual Golf Tournament
Jonathan Spaeth	Team Deconstructing Cancer	Andy Thieman	Katie Waters
Dara Spearman	Team DeFREEZING Cancer	Kate Thomas	Watertown Middle School
Allyson Spring	Team D.R.E.A.M	Kennedy Thomason	The Wawa Foundation
Troy Springer and Cinzia Rolling	Team Droplet Like It's Hot	Robin Thureau	Weddington Middle School
Stacie Sheely's Campaign Team	Team Fearless Dragons	Tim Houterloot's Campaign Team	Weiler Foundation
Stacy Goldstein's Campaign Team	Team Fight Cancer	TNT Caballeros	Greg Weimer
Nathan Stallings	Team Fire Hearts	Tocqueville Asset Management	Kristie Welte
Dean Stamoulis	Team Go Gold	Megan Toner	West Ridge Middle School
Stanley Koehl's Campaign Team	Team Gordo's Groupies	Grace Toomey	Whaboom
Nick Starr	Team Hamlin's Cure-saders	Brianna Torgerson	When Pigs Fly: Making the Impossible Possible
Stater Bros. Markets	Team Heart Roots	Tour 2 Cure	Jenna Whitehead
Kevin Steckley	Team Hero - Luke Hatfield	Cara Tovissi	Nancy Whitman
Donald and Margaret Steiner	Team Ho'omau	Matt Tovrog	Jessie Wiener
Sullie Stephens	Team Hope	Chris Townsend	Wilkes & McHugh
Kate Stevens	Team Hudson	Tracy Johnson's Campaign Team	Will Rigby's Campaign Team
Anna Stewart	Team Husky	Larry W. Treen Jr.	Will Rogers's Campaign Team
Brad Stinson	Team Hutton 1045	Yvette Tremonti	William Mason High School
Raul Storey-Rojas	Team Jim Thorpe	Trent Jackson's Campaign Team	Rob Williams
Justin Stout	Team JumpingForJoy	Annie Trimberger	Dwayne Wilson
Abigail Stoy	Team Justin	Trividia Health, Inc.	JP Witkop
Stratford School at Osgood	Team Leticia Juarez in Memory of Pamela Johnston	Dominic Tully	Wolfpack (Hunting For A Cure)
Stephen Strickland	Team Live Love and Adventure - Patty Leemhuis	Turkey Shoot Golf Tournament	Stephanie Wong
Saunder Strong	Team Lori	Twiggy's Dream Team	World of Warriors
Heather Stubblefield	Team Lymph-busters	Bryce Unger	Jillian Wright
Daniel Sullivan	Team Maddie's Mission	Grace Unger	Randy Writz
Katie Sullivan Taulane	Team Mighty	Sohan Upadhya	Manuela Yanez
Vonnie Sullivan	Team NARS	Lauren Valentine	Preston York
Summer Hall's Campaign Team	Team Nike	Valerie Lewis's Campaign Team	Matthew Yost
Susan Rheingold's Campaign Team	Team Panthers Against Cancer	VALiant Warriors	Yvette Tremonti's Campaign Team
Skylar Takac	Team Phoenix	Brent VanLoo	Jake Zaas
Scott Takinen	Team PwC: Run for Richard	Nicholas Van Zandt	Hala Ziady
Mona Talukdar	Team Reid	Julia Vasco	Claire Ziegler
Tammy Motley's Campaign Team	Team Scream Survivor	Mr. and Mrs. Leo Vecellio	Bella Zinkin and Sienna Saxton
Wine Tasting	Team Soulumination	Carmen Vega	
Mark Taylor	Team Stanley	Anthony Velardi	
Team EMI	TEAM SURVIVOR	Zarmeena Vendal, MD	
Team Alaska Airlines	Team Teeny for the Cure	Banner Vicary	
Team All Stars	Team Tobon	Victoria Santos's Campaign Team	
Team Art	Team Turn Up For The Cure	Jenny Vipperman	
Team b. strong	Team Victory Royale	Nick Vizzoca	
Team Baja	Team Ward Law Group	Vystar Credit Union	
Team Beat 41 - Lily Johnson	Team Wendy's	Devon Wagner	
Team Beeches Beat Cancer	Team Wishes for a Cure - Heather Hibbard	Walgreens	
Team Blumenfeld-Waterman	Team Wishful Workers - Jennifer Oz	Mike Wall	
Team Bucket List Cure Cancer	Team Worth the Fight	Patrick Wall	
Team Chemo Sabe	Team Zephyr	Amy Wallner	
Team Chrisman	Terumo BCT	Gregory Ward	
Team Coast to Coast	The Three MuskeCUREs	Janine Ward	
Team Crushers	The Tiger Stripes	Lindsey Ward	
Team CUREageous		Wayne Warrington	
		Warriors 4 LLS	

Legacy Circle

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of \$10,000 or more were received this year.

Edward Darden Baines*
Michelle Bargeron*
Alice Ann Bien*
Joyce Boice*
Margaret and John Bruner*
William P. Caloccia*
Kalpana Chakraborty in memory of Shib Chakrabarty
Roseann Comstock*
Alan Cook*
Anna Cryder*
Gregory D'Angelo in memory of Diane D'Angelo
Robert DeVolder*
Nicholas Dissler*
Peggy and Margaret Dupaquier*
Robert Ellis*

Judith Erickson*
Anita Foster*
Grace Fram*
Barbara Frattura* in memory of Pasquale (Pat) R. Frattura
Nancy Hall*
Victoria Harris*
Ferris Hartman*
Susanne Hassell*
Alice Hejl*
Barbara Hellman*
Rowena Huddle*
Lewis Kaplan*
George Keleher*
John Kellenyi**
Wayne Kenfield*
James Kimble*
Else Korb*
Legion Kramer*
Martha Lacy in memory of William R. Lacy
Albert Lee
Sanford Levinson in memory of Elaine Levinson

Howard Bruce Linden in memory of Walter William Linden
Debra Linick
Margaret MacMurray*
Ronald Marony*
Elaine Meyers-Matloff*
Emily Papapietro*
Mary Alice Parks*
Mary Perluss*
Renee Pittin*
Gretchen Pressburg
Eugene Regener, III*
Michael Rinaldi*
Gene Rochlin*
Sally Rossiter*
Gail Secrist*
Bruno and Irma Selmi*
Roselle Shaw*
DJ Smith-Brooks*
Robert Snincak*
Wanda Starkey*
Jo Ann Taylor*
Mitchell Tobin and Susan Jacobson in memory of Nancy Tobin

Elizabeth Duffy Traynham*
Robert Trusler*
Peter Vlahakos*
Alice Wambach*
Abie Werth*
Thomas West*
Harvey White*
Mark Wiener*
John Wilhelm*
Catherine Woodfield*
Shirley and Hal Wright*
Muriel Yuster*
Anonymous (6)

* Deceased

† We proudly recognize John Kellenyi, generous, longtime supporter and Beat AML Campaign co-chair, for his leadership, compassion, and commitment

Endowment Funds

The Bill Beattie Memorial Endowment Fund (Alberta)
de Villiers Endowment Fund
GlaxoSmithKline Foundation
-Gertrude B. Elion Endowment Fund
GlaxoSmithKline, Inc. Research Fund

Jane Elissa/Charlotte Meyers Endowment Fund
Jim Jacobs Leukemia Research Fund
Mary & Robert Bronstein Memorial Fund

The Rachel Kudish Fund
The Rae Endowment Fund (Ontario)
Reich Endowment Fund
Thomas M. Ford Memorial Fund
The United Food and Commercial Workers (Canada) Endowment Fund

The Virginia Major Brooks Memorial Endowment Fund
Vrushali Ranadive Fellowship Fund

Research Portfolios

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.

Mission Portfolio is funded in part by Alvin H. Baum Family Fund, the Andrew J. Gargiso Foundation, Ellen Arrington, Adel and Tom Barry, Breeden-Adams Foundation, Bente and Jim Carter, Jay Torborg and Diana Dickinson, Hedinger Family Foundation, The Joseph and Catherine Johnson Family Foundation, The Kahn Foundation, William and Sheila Kern, Lois and Richard England Family Foundation, The Luppe and Paula Luppen Family Foundation, The Ping Y. Tai Foundation, Inc., David and Patricia Quast, Audrey Sachs, Michael L. Smith, Tom & Virginia Jennaro Family Foundation, Inc. and anonymous.

Patient Support & Public Policy Portfolio is funded in part by Allegheny Foundation, The John and Frances Beck Family Foundation, UCLA Kaiser Permanente Center of Health Equity, and anonymous.

The Harry T. Mangurian Jr. Beat AML Project is funded in part by Dwight Anderson, Avantor Sciences Foundation, Monica and Timothy Babich, Anna and Dean Backer, Nancy Boeck, the Boldt Family Philanthropy Fund, Cal Turner Family Foundation, The Charles Engelhard Foundation, The Charles T. Bauer Charitable Foundation, Dan and JoAnne Coolidge, Michael and Liz Copley, Cycle for Carly, Jim and Elaine Day, Doug Schlegel Charitable Foundation, Ed & H Pillsbury Foundation, Enterprise Electric LLC, Cynthia and Frank Gasztonyi, John Geoghegan, The Harry T. Mangurian Jr. Foundation, Inc., Ray Haupt, Kathleen and Mark Helge, the Hildegard D. Becher Foundation, Inc., HM Insurance Group, John and Kristin Hyland, Immucor, Indorama Ventures, Jochum-Moll Foundation, John and Mary Franklin Foundation, Inc., Mary Beth and Christopher Kearns, John Kellenyi (deceased), The Kroll Family Foundation, Joyce and Larry Lacerte, Dr. Hillard M. Lazarus, Jeannie and Steve Lieblich, Susan and Peter Lindahl, Judy and Charlie Lynch, The Lyon Family Foundation, William McNitt, Daniel Mendez, The Michael Treinen Foundation, The Nashville Wine Auction, The Norcross Foundation, Inc. In Memory of Herrick F. Norcross, Jr. (Rick), Donald Porteous, Rahr Corporation, Jason and Heather Redpath, Andrea Reid, Barbara and Brent Reid, Gene Rochlin, the Roderick Seward, Flossie Radcliffe and Helen M. Galloway Foundation, ROMA Charitable Foundation, Pat and Jeff Sachs, Barb and Tom Stayton, Margaret and Donald Steiner, Mona Carlton Stogner and Grey Stogner, Team b.strong, Karin Tollefson, Natan and Beth Vaisman, and anonymous (2 donors).

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by The Alice Lawrence Foundation, Inc., The Edward J. Phillips Family Foundation, The Carlson Family Foundation, Greater Milwaukee Foundation, Inc., Corrine and Jon Merksamer, and Julianne Ward.

Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Lisa Norcia Cheskin and Barry Cheskin and the Eric Scherbarth Leukemia Research Foundation, Inc.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Alex Boggs, Steven and Sandy Brannon, and Sharon and Paul Dillon.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Leslie and Larry Nance.

Hodgkin Lymphoma Research Portfolio is funded in part by AM Charity Fund and Terry D. and Carol A. Agness Charitable Trust.

Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by John and Nonnie Barbey, Lisa Norcia Cheskin and Barry Cheskin, Cristine and Timothy Lindenfelser, Robert and Nancy Rosen, Lois and Jerry Rosenblum, and Michael L. Smith.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Donna Hartman, and Rochelle Klutch.

Immunotherapy Portfolio is funded in part by The Alice Lawrence Foundation, Inc. and Janet Faulkner.

Information Resource Center (IRC) is funded in part by Adel Barry.

Lymphoma Diagnostics Program is funded in part by Chiyoko Furukawa.

Therapy Acceleration Program is funded in part by Robert and Nancy Rosen, Lois and Jerry Rosenblum, and Allen Zachary.

The Susan Lang Pay-It-Forward Transportation Assistance Program is funded in part by The Grainger Foundation, Lang / Stiglitz Family Fund, and anonymous.

Pediatric Initiative is funded in part by ACE Family Foundation, Daniel Adelson ("Keychains 4 Kids"), Angela Blank, Bobby & Steve's Auto World Youth Foundation, William and Tamea Bock, Steven and Sandy Brannon, Charles and Chris Carroll, Don & Lorraine Freeberg Foundation, F. M. Kirby Foundation, Inc., Dianne Franco, The Harry T. Mangurian Jr. Foundation Inc., Higgins Family Charitable Foundation, Jack Buncher Foundation, Doug and Kristen Johanson, Kayleen Larson Legacy Foundation, Alexander Macdonald, Nimick Forbesway Foundation, Lynne and Greg O'Brien, Lydia and Robert Odle, The Orokawa Foundation, Inc., Fred and Cherie Pond, The Rhoda and David Chase Family Foundation, Inc., Joan and Paul Rubschlager, Brian and Maggie Schilling, The Wawa Foundation, and anonymous.

Precision Medicine Initiative is funded in part by The Harry T. Mangurian Jr. Foundation, Inc.

Leadership

National Board

Volunteers serve on our National Board of Directors providing leadership and governance to help find blood cancer cures.

Officers

Chairman of the Board

Jorge Benitez
Fort Lauderdale, FL

Vice Chair

Bart Sichel
Bucks County, NJ

Secretary/Treasurer

Ralph E. Lawson, FHFMA, CPA
Parkland, FL

At Large

Kathleen Meriwether
Ernst & Young, LLP
Philadelphia, PA

Directors

William G. Behnke
The Behnke Group
San Antonio, TX

Peter Brock
Brock Development
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Renzo Canetta, MD
Madison, CT

Casey Cunningham, MD.
Sante Ventures
Houston, TX

William S. Dalton, MD, PhD
2Gen
Tampa, FL

Samuel Eberts, III
Chapel Hill, NC

Christopher Flowers, MD
Emory University
Atlanta, GA

Janice Gabrilove, MD.
Icahn School of Medicine
at Mt. Sinai
New York, NY

Bernard H. Garil
Delray Beach, FL

John Greene
Salesforce
San Francisco, CA

Francie Heller
Arabesque Asset Management
New York, NY

Michelle LeBeau, PhD
University of Chicago
Comprehensive Cancer Center
Chicago, IL

Connie L. Lindsey
Northern Trust
Chicago, IL

Ruben Mesa, MD
Mays Cancer Center
San Antonio, TX

Ted Moroz
The Beer Store Ontario
Toronto, ON, Canada

Harry Moseley
Zoom
San Jose, CA

Lynne O'Brien
McLean, VA

Marla Persky, JD
WOMN LLC
Ridgefield, CT

Donald Proctor
Bk97 Digital
Walnut Creek, CA

Robert Rosen
Greyhawk Capital Advisors LLC
West Palm Beach, FL

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Jeff Sachs
Jones Lang LaSalle
Duluth, GA

Kenneth Schwartz
Ernst & Young, LLP
New York, NY

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Executive Leadership

The Leukemia & Lymphoma Society

Louis J. DeGennaro, PhD
President & Chief Executive Officer

Danielle Gee
Chief of Staff

Kathy Griesenbeck
Executive Vice President
Chief Relationship Officer

Marcie Klein
Executive Vice President
Chief Communications Officer

Margo Lucero
Executive Vice President
Corporate Partnerships and
Development

JR Miller
Executive Vice President
Chief Financial Officer

Gwen Nichols, MD
Executive Vice President
Chief Medical Officer

Tom Osgood
Executive Vice President
Chief Human Resources Officer

Coker Powell
Executive Vice President
Products & Campaign Development

Vanessa White
Executive Vice President
Chief Development Officer

The Leukemia & Lymphoma Society of Canada

Alicia Talarico
President
Canadian Operations

Offices

United States:
[https://www.lls.org/
chapter-selection-page](https://www.lls.org/chapter-selection-page)

Canada:
[http://www.llscanada.org/
chapter-selection-page](http://www.llscanada.org/chapter-selection-page)

**BEATING
CANCER
IS IN
OUR BLOOD.[®]**

3 International Drive, Suite 200, Rye Brook, NY 10573 • 914.949.5213

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.